Dactinomycin Compositions and Methods for Treating Myelodysplastic Syndromes and Acute Myeloid Leukemia - Patent application
Nanoparticle-encapsulated dactinomycin addresses the lack of effective treatments for MDS and AML by providing targeted therapy with reduced side effects, effectively treating NPM1-mutant AML and other forms of the diseases.
Patent Information
- Application Number
- JP2022025700
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-05-02
- Filing Date
- 2022-02-22
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2037-09-13
AI Technical Summary
Effective treatment options for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), particularly NPM1-mutant AML, remain limited.
A composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, specifically using polymers like PLA-mPEG or PLGA-mPEG with a size range of 100-200 nm, is administered to treat MDS and AML, including NPM1-mutant AML.
The nanoparticle-encapsulated dactinomycin provides targeted therapy for MDS and AML, reducing side effects like mucositis and effectively treating the diseases, including achieving remission in NPM1-mutant AML.
Smart Images

Figure 0007596323000014 
Figure 0007596323000015 
Figure 0007596323000016
Abstract
Description
[Technical field]
[0001] Related Applications This application claims the benefit of and priority to U.S. Provisional Application No. 62 / 394,104, filed September 13, 2016, U.S. Provisional Application No. 62 / 444,330, filed January 9, 2017, and U.S. Provisional Application No. 62 / 500,459, filed May 2, 2017, the contents of each of which are incorporated herein by reference in their entirety.
[0002] The present disclosure is directed to the field of molecular biology relating to genetic testing, diagnosis, and treatment of patients with myelodysplastic syndromes or cancer. [Background technology]
[0003] NPM1-mutated acute myeloid leukemia (AML) is a unique leukemia that accounts for one-third of AML cases in adults.
[0004] Myelodysplastic syndromes (MDS) encompass a group of diverse bone marrow disorders that affect red blood cells, white blood cells, and platelets in the bone marrow. Progenitor stem cells may fail to mature and accumulate in the bone marrow or may have a short life span, resulting in fewer mature blood cells circulating than normal. The incidence of MDS is approximately 4-5 per 100,000 population, increasing to 20-50 per 100,000 over the age of 60. MDS progresses to acute myeloid leukemia (AML) in approximately 30% of cases. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Hill,CRet al.Clin.Pharmacokinet.(2014)53:741-751 [Non-Patent Document 2] Walsh, C. et al.Br J Clin Pharmacol(2016)81:989-998 [Non-Patent Document 3] Falini, B. et al. “Cytoplasmic nucleo-phosmin in acute myelogenous leukemia with a normal karyo-type” N.Engl.J.Med.2005;352:254-266 [Non-Patent Document 4] Cancer Genome Atlas Research Network. “Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia”N.Engl.J.Med.2013;368:2059-2074 [Non-Patent Document 5] Falini, B. et al. “Acute myeloid leukemia with mutated nucleophosmin (NPM1):any hope for a targeted therapy?”Blood Rev.2011;25:247-254 [Non-Patent Document 6] "Common Terminology Criteria for Adverse Events v3.0 (CTCAE)", published August 9, 2006 [Non-Patent Document 7] Osathanondh,R.et al.Cancer 1975;36:863-866 [Non-Patent Document 8] Burger K.et al.J.Biol.Chem.2010;285:12416-12425 Summary of the Invention [Problem to be solved by the invention]
[0006] There is a long-felt but unmet need for effective treatment of MDS and AML, including NPM1-mutated AML. [Means for solving the problem]
[0007] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising PLA-mPEG, the nanoparticles having an average size of about 100 nm to about 200 nm.
[0008] In one embodiment, the PLA-mPEG comprises from about 5% mPEG to about 50% mPEG (eg, 25%) by weight.
[0009] In one embodiment, the PLA-mPEG comprises from about 15% mPEG to about 35% mPEG (eg, 25%) by weight.
[0010] In one embodiment, the molecular weight of the PLA-mPEG is from about 25,000 Da to about 35,000 Da.
[0011] In one embodiment, the molecular weight of the PLA-mPEG is about 30,000 Da.
[0012] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising PLA-mPEG, the molecular weight of the PLA-mPEG being between about 25,000 Da and about 35,000 Da.
[0013] In one embodiment, the molecular weight of the PLA-mPEG is about 30,000 Da.
[0014] In one embodiment, the PLA-mPEG comprises from about 5% mPEG to about 50% mPEG (eg, 25%) by weight.
[0015] In one embodiment, the PLA-mPEG comprises from about 15% mPEG to about 35% mPEG (eg, 25%) by weight.
[0016] In one embodiment, the nanoparticles have an average size of about 100 nm to about 200 nm.
[0017] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising PLGA-mPEG, the nanoparticles having an average size of about 100 nm to about 200 nm.
[0018] In one embodiment, the PLGA has a lactic acid:glycolic acid molar ratio of about 40:60 to about 60:40.
[0019] In one embodiment, the PLGA has a lactic acid:glycolic acid molar ratio of about 50:50.
[0020] In one embodiment, the PLGA-mPEG comprises from about 5% mPEG to about 50% mPEG (eg, 35%) by weight.
[0021] In one embodiment, the PLA-mPEG comprises from about 25% mPEG to about 45% mPEG (eg, 35%) by weight.
[0022] In one embodiment, the molecular weight of the PLGA-mPEG is from about 17,000 Da to about 27,000 Da.
[0023] In one embodiment, the molecular weight of the PLGA-mPEG is about 22,000 Da.
[0024] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising PLGA-mPEG, the molecular weight of the PLGA-mPEG being between about 17,000 Da and about 27,000 Da.
[0025] In one embodiment, the molecular weight of the PLGA-mPEG is about 22,000 Da.
[0026] In one embodiment, the PLGA has a lactic acid:glycolic acid molar ratio of about 40:60 to about 60:40.
[0027] In one embodiment, the PLGA has a lactic acid:glycolic acid molar ratio of about 50:50.
[0028] In one embodiment, the PLGA-mPEG comprises from about 5% mPEG to about 50% mPEG (eg, 35%) by weight.
[0029] In one embodiment, the PLA-mPEG comprises from about 25% mPEG to about 45% mPEG (eg, 35%) by weight.
[0030] In one embodiment, the nanoparticles have an average size of about 100 nm to about 200 nm.
[0031] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising poly(lactic acid) (PLA), the nanoparticles having an average size of about 100 nm to about 200 nm.
[0032] In one embodiment, the PLA is ester terminated.
[0033] In one embodiment, the molecular weight of the PLA is from about 10,000 Da to about 18,000 Da.
[0034] In one embodiment, the PLA is acid terminated.
[0035] In one embodiment, the molecular weight of the PLA is from about 18,000 Da to about 24,000 Da.
[0036] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising poly(lactic acid) (PLA), the PLA having a molecular weight of about 10,000 Da to about 18,000 Da.
[0037] In one embodiment, the PLA is ester terminated.
[0038] In one embodiment, the nanoparticles have an average size of about 100 nm to about 200 nm.
[0039] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising poly(lactic acid) (PLA), the PLA having a molecular weight of about 18,000 Da to about 24,000 Da.
[0040] In one embodiment, the PLA is acid terminated.
[0041] In one embodiment, the nanoparticles have an average size of about 100 nm to about 200 nm.
[0042] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising one or more polymers, and further comprising a surfactant.
[0043] In one embodiment, the surfactant comprises about 0.1% to about 5% by weight of each nanoparticle.
[0044] In one embodiment, the surfactant is polyvinyl alcohol.
[0045] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the nanoparticles comprising one or more polymers, the nanoparticles having an average size of about 100 nm, 101 nm, 102 nm, 103 nm, 104 nm, 105 nm, 106 nm, 107 nm, 108 nm, 109 nm, 110 nm, 111 nm, 112 nm, 113 nm, 114 nm, 115 nm, 116 nm, 117 nm, 118 nm, 119 nm, 200 nm, 201 nm, 202 nm, 203 nm, 204 nm, 205 nm, 206 nm, 207 nm, 208 nm, 209 nm, 300 nm, 301 nm, 302 nm, 303 nm, 304 nm, 305 nm, 306 nm, 307 nm, 308 nm, 309 nm, 400 nm, 401 nm, 402 nm, 403 nm, 404 nm, 405 nm, 406 nm, 407 nm, 408 nm, 409 nm, 500 nm, 510 nm, 511 nm, 512 nm, 513 nm, 514 nm, 515 nm, 516 nm, 517 nm, 518 nm, 520 nm, 521 nm, 522 nm, 523 nm, 524 nm, 525 nm, 526 nm, 527 nm, 528 nm, 529 nm, 530 nm, 531 nm, 532 nm, 533 nm, 534 nm, 535 nm, 536 17nm, 118nm, 119nm, 120nm, 121nm, 122nm, 123nm, 124nm, 125nm, 126nm, 127nm, 128nm, 129nm, 130nm, 131 nm, 132nm, 133nm, 134nm, 135nm, 136nm, 137nm, 138nm, 139nm, 140nm, 141nm, 142nm, 143nm, 144nm, 145nm , 146nm, 147nm, 148nm, 149nm, 150nm, 151nm, 152nm, 153nm, 154nm, 155nm, 156nm, 157nm, 158nm, 159nm, 1 60nm, 161nm, 162nm, 163nm, 164nm, 165nm, 166nm, 167nm, 168nm, 169nm, 170nm, 171nm, 172nm, 173nm, 174 nm, 175 nm, 176 nm, 177 nm, 178 nm, 179 nm, 180 nm, 181 nm, 182 nm, 183 nm, 184 nm, 185 nm, 186 nm, 187 nm, 188 nm, 189 nm, 190 nm, 191 nm, 192 nm, 193 nm, 194 nm, 195 nm, 196 nm, 197 nm, 198 nm, 199 nm, or 200 nm.
[0046] The present disclosure relates to a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising one or more polymers, the nanoparticles having an average size of about 100 nm to about 110 nm, about 105 nm to about 115 nm, about 110 nm to about 120 nm, about 115 nm to about 125 nm, about 120 nm to about 130 nm, about 125 nm to about 135 nm, about 130 nm to about 140 nm, about 135 nm to about 145 nm, about 130 nm to about The present invention provides a composition having a diameter of about 140 nm, about 135 nm to about 145 nm, about 140 nm to about 150 nm, about 145 nm to about 155 nm, about 150 nm to about 160 nm, about 155 nm to about 165 nm, about 160 nm to about 170 nm, about 165 nm to about 175 nm, about 170 nm to about 180 nm, about 175 nm to about 185 nm, about 180 nm to about 190 nm, about 185 nm to about 195 nm, or about 190 nm to about 200 nm.
[0047] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising one or more polymers and comprising about 5% to about 15% by weight of dactinomycin.
[0048] The present disclosure provides methods for treating myelodysplastic syndrome (MDS) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compositions comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles containing one or more polymers as described herein.
[0049] The present disclosure provides methods for treating cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of any of the compositions comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles containing one or more polymers as described herein.
[0050] In one embodiment, the cancer is acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), colorectal cancer, neuroendocrine cancer, esophageal cancer, and / or gastrointestinal stromal tumor (GIST).
[0051] The present disclosure relates to a method for treating myelodysplastic syndromes (MDS) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compositions comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles containing one or more polymers as described herein, the method further comprising administering a therapeutically effective amount of at least one additional chemotherapeutic agent, the chemotherapeutic agent being a topoisomerase inhibitor, a platinum-based therapeutic agent, an anthracycline antibiotic, a taxane, The method includes administering to the subject a therapeutic agent selected from the group consisting of a tyrosine kinase inhibitor, a nucleoside analog, an FMS-like tyrosine kinase 3 (FLT3) inhibitor, and a hypermethylation inhibitor, wherein the molar ratio of the topoisomerase inhibitor, platinum-based therapeutic agent, anthracycline antibiotic, taxane, tyrosine kinase inhibitor, nucleoside analog, FLT3 inhibitor, and hypermethylation inhibitor to dactinomycin is 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, less than 1:1, or any ratio therebetween.
[0052] The present disclosure provides methods for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compositions comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles containing one or more polymers as described herein, the method further comprising administering a therapeutically effective amount of at least one additional chemotherapeutic agent, the chemotherapeutic agent being selected from the group consisting of topoisomerase inhibitors, platinum-based therapeutic agents, anthracycline antibiotics, taxanes, tyrosine kinase inhibitors, nucleoside analogs, FLT3 inhibitors, and hypermethylation inhibitors, wherein the molar ratio of the topoisomerase inhibitors, platinum-based therapeutic agents, anthracycline antibiotics, taxanes, tyrosine kinase inhibitors, nucleoside analogs, FLT3 inhibitors, and hypermethylation inhibitors to dactinomycin is 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, less than 1:1, or any ratio therebetween.
[0053] Any of the compositions described herein are suitable for use in treating cancer (e.g., acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), colon cancer, neuroendocrine cancer, esophageal cancer, and / or gastrointestinal stromal tumor (GIST)) in a subject, and / or are suitable for use in treating MDS in a subject. Any of the compositions of the present disclosure are administered to a subject systemically, intravenously, by infusion, or orally.
[0054] Any of the compositions of the present disclosure may be administered to a subject once daily, once weekly, twice weekly, or once every three weeks.
[0055] In some embodiments, any of the compositions of the present disclosure are administered to a subject once daily, once weekly, twice weekly, or once every three weeks, and the treatment further comprises a one-week, two-week, three-week, or four-week rest period between or between administrations.
[0056] Any of the compositions of the present disclosure are administered to a subject once or twice over a period of one, two, or three weeks.
[0057] In some embodiments, any of the compositions of the present disclosure are administered to a subject once or twice over a period of 1, 2, or 3 weeks, and the treatment further comprises a 1-week, 2-week, 3-week, or 4-week rest period between or during the administration period.
[0058] In one embodiment, the methods of the disclosure include methods where the subject has or is at risk of developing mucositis.
[0059] The methods of the present disclosure include those where the subject is simultaneously treated with one or more anti-inflammatory and / or antioxidant agents for symptoms of mucositis.
[0060] The methods of the present disclosure include those wherein the subject has been pretreated for symptoms of mucositis with one or more anti-inflammatory and / or antioxidant agents prior to administration of any of the compositions described herein.
[0061] In one embodiment, the compositions and methods of the disclosure provide a therapeutically effective amount of dactinomycin having an AUC of about 0.05 to about 2.0 mg min / L. ∞ The present invention includes compositions and methods that result in
[0062] In one embodiment, the disclosed compositions and methods provide a therapeutically effective amount of dactinomycin having an AUC of about 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.0, 1.05, 1.10, 1.15, 1.20, 10.25, 1.30, 1.35, 1.40, 1.45, 1.50, 1.55, 1.60, 1.65, 1.70, 1.75, 1.80, 1.85, 1.90, 1.95, or 2.0 mg·min / L. ∞ The present invention includes compositions and methods that result in
[0063] In one embodiment, the compositions and methods of the disclosure provide a therapeutically effective amount of dactinomycin having an AUC of about 0.05 to about 1.0 mg min / L. ∞ The present invention includes compositions and methods that result in
[0064] In one embodiment, the compositions and methods of the present disclosure provide a therapeutically effective amount of dactinomycin having a C of about 1 ng / mL to about 30 ng / mL. max The present invention includes compositions and methods that result in
[0065] In one embodiment, the disclosed compositions and methods provide a therapeutically effective amount of dactinomycin having a C of about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, or 30 ng / mL. max The present invention includes compositions and methods that result in
[0066] In one embodiment, the compositions and methods of the present disclosure provide a therapeutically effective amount of dactinomycin having a C of about 1 ng / mL to about 20 ng / mL. max The present invention includes compositions and methods that result in
[0067] In one embodiment, the disclosed compositions and methods provide a therapeutically effective amount of dactinomycin having a C of about 1 ng / mL to about 5 ng / mL, about 5 ng / mL to about 10 ng / mL, about 10 ng / mL to about 15 ng / mL, or about 15 ng / mL to about 20 ng / mL. max The present invention includes compositions and methods that result in
[0068] In one embodiment, the compositions and methods of the present disclosure include those wherein about 60% to about 90% of the dactinomycin is released from the nanoparticles after 2 days, 3 days, 4 days, or 5 days.
[0069] In one embodiment, the compositions and methods of the disclosure include those where about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90% of the dactinomycin is released from the nanoparticles after 2, 3, 4, or 5 days.
[0070] In one embodiment, the compositions and methods of the present disclosure include those where about 60% to about 90% of the dactinomycin is released from the nanoparticles after 3 days.
[0071] In one embodiment, the compositions and methods of the disclosure include compositions and methods where about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90% of the dactinomycin is released from the nanoparticles after 3 days.
[0072] In one embodiment, the compositions and methods of the present disclosure include those wherein about 70% to about 80% of the dactinomycin is released from the nanoparticles after 2 days, 3 days, 4 days, or 5 days.
[0073] In one embodiment, the compositions and methods of the present disclosure include those where about 70% to about 80% of the dactinomycin is released from the nanoparticles after 3 days.
[0074] The present disclosure also provides a process for preparing any of the compositions of the present disclosure, comprising: (i) adding a solution of dactinomycin in an organic solvent to a solution of a polymer in an organic solvent until the ratio of polymer:API is 10:1 (wt / wt); (ii) vortexing the solution of (i) until homogenous; (iii) adding the solution of (ii) dropwise to an aqueous phase containing 2% (w / w) polyvinyl alcohol having a molecular weight of 9,000-10,000 Da that is 80% hydrolyzed, while vortexing the aqueous phase at high speed, until the volume ratio of the solution of (ii) to the aqueous phase is about 1:7, thereby forming a nanoparticle emulsion; (iv) vortexing the emulsion of (iii); (v) sonicating the emulsion of (iv) at 0° C. for a few minutes, and then pouring the emulsion into a stirred aqueous solution containing 2% (w / w) polyvinyl alcohol and continuing to stir until the organic solvent has evaporated; and, optionally, (vi) purifying the resulting composition by centrifugation at 14,000×rpm for about 30 minutes; (vii) After discarding the supernatant of (vi), washing the obtained nanoparticles with ddHO and centrifuging at 14,000×rpm for 30 minutes; (viii) resuspending the product of (viii) in ddH2O followed by centrifugation at 3500 x rpm for 5 minutes; (ix) collecting the supernatant of (viii) and concentrating it using an Amicon® Ultra Centrifugal filter (50 kD cutoff) followed by centrifugation at 14,000×rpm for 10 minutes to remove free dactinomycin.
[0075] In one embodiment, in a process for preparing any of the compositions of the present disclosure, the amount of free dactinomycin in the composition is less than 5% by weight, less than 4% by weight, less than 3% by weight, less than 2% by weight, or less than 1% by weight of the amount of dactinomycin encapsulated in the nanoparticles.
[0076] The present disclosure provides dactinomycin compositions, i.e., compositions comprising dactinomycin, e.g., dactinomycin encapsulated in or associated with nanoparticles. As used herein, dactinomycin may be referred to interchangeably as actinomycin-D, Act-D, ActD, Act D, etc.
[0077] The present disclosure provides a method for treating cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of a composition of the present disclosure. In certain embodiments, the cancer can be acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), colorectal cancer, neuroendocrine cancer, esophageal cancer, or gastrointestinal stromal tumor (GIST). In certain embodiments, the cancer can be acute myeloid leukemia (AML). In certain embodiments, the AML can be NPM1-mutated AML or wild-type AML. In certain embodiments, the AML can be NPM1-mutated AML.
[0078] The present disclosure provides a method for treating myelodysplastic syndrome (MDS) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the present disclosure.
[0079] In certain embodiments, the method may further comprise administering a therapeutically effective amount of one or more additional chemotherapeutic agents selected from the group consisting of a topoisomerase inhibitor, a platinum-based therapeutic agent, an anthracycline antibiotic, a taxane, a tyrosine kinase inhibitor, a nucleoside analog, an FLT3 inhibitor, and a hypermethylation inhibitor. In certain embodiments, the topoisomerase inhibitor may comprise etoposide. In certain embodiments, the platinum-based therapeutic agent may comprise cisplatin. In certain embodiments, the anthracycline may comprise daunorubicin, doxorubicin, epirubicin, or idarubicin. In certain embodiments, the taxane may comprise paclitaxel or docetaxel. In certain embodiments, the tyrosine kinase inhibitor may comprise imatinib. In certain embodiments, the nucleoside analog may comprise cytarabine, gemcitabine, or capecitabine. In certain embodiments, FLT3 inhibitors may include Rydapt® (midostaurin), sorafenib, lestaurtinib, quizartinib, ponatinib, crenolanib, or gilteritinib. In certain embodiments, hypermethylation inhibitors may include azacitidine, decitabine, and zebularine.
[0080] In certain embodiments, the molar ratio of topoisomerase inhibitor, platinum-based therapeutic agent, anthracycline antibiotic, taxane, tyrosine kinase inhibitor, or nucleoside analog to dactinomycin is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, or any ratio therebetween. In certain embodiments, the molar ratio is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, or any ratio therebetween. In certain embodiments, the molar ratio is 7:1, 6:1, 5:1, 4:1, 3:1, or any ratio therebetween. In certain embodiments, the molar ratio is about 5:1. In a particular embodiment, the molar ratio is 5:1.
[0081] The present disclosure provides methods for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the present disclosure and at least one of etoposide, cytosine arabinoside (ara-C, cytarabine), and oxaliplatinum.
[0082] The present disclosure provides methods for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the present disclosure and cytarabine.
[0083] The compositions of the present disclosure may further comprise a therapeutically effective amount of an anti-inflammatory agent, an antioxidant, or a combination thereof. The methods of the present disclosure may further comprise administering to the subject a therapeutically effective amount of an anti-inflammatory agent, an antioxidant, or a combination thereof.
[0084] Anti-inflammatory agents of the present disclosure may include pentoxifylline and / or nonsteroidal anti-inflammatory drugs (NSAIDs).
[0085] Antioxidants of the present disclosure may include vitamin C, N-acetylcysteine, amifostine, or retinoic acid (e.g., all-trans-retinoic acid). In certain embodiments, antioxidants of the present disclosure may include vitamin C, retinoic acid (e.g., all-trans-retinoic acid), or a combination thereof.
[0086] In certain embodiments, the anti-inflammatory agents may include pentoxifylline and / or NSAIDs, and the antioxidants may include vitamin C, or retinoic acid (e.g., all-trans-retinoic acid). In certain embodiments, the anti-inflammatory agents may include pentoxifylline and / or NSAIDs, and the antioxidants may include vitamin C, retinoic acid (e.g., all-trans-retinoic acid), or combinations thereof.
[0087] In certain embodiments, the molar ratio of the anti-inflammatory agent, antioxidant, or combination thereof to dactinomycin is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, or any ratio therebetween.
[0088] The disclosed method includes combining a composition of the disclosure, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles; (a) an anti-inflammatory agent, (b) an antioxidant, and (c) administering at least one of the combinations of the anti-inflammatory agent and the antioxidant, wherein the dactinomycin and the anti-inflammatory agent, the antioxidant, or any combination thereof, are administered simultaneously.
[0089] The disclosed method includes combining a composition of the disclosure, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles; (a) an anti-inflammatory agent, (b) an antioxidant, and (c) administering at least one of the combinations of the anti-inflammatory agent and the antioxidant, wherein the dactinomycin and the anti-inflammatory agent, the antioxidant, or any combination thereof, are administered sequentially.
[0090] The disclosed compositions comprising dactinomycin may be administered systemically to a subject. In certain embodiments, the disclosed compositions comprising dactinomycin may be administered intravenously or by infusion. In certain embodiments, the disclosed compositions comprising dactinomycin may be administered orally. In certain embodiments, the disclosed compositions comprising dactinomycin may be administered in the form of a tablet or capsule.
[0091] Compositions of the present disclosure comprising dactinomycin, e.g., compositions comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, may be administered at a therapeutically effective amount of the composition of 1 to 30 μg / kg / day, inclusive. In certain embodiments, compositions of the present disclosure comprising dactinomycin may be administered at a therapeutically effective amount of the composition of 10 to 20 μg / kg / day, inclusive, or 10 to 15 μg / kg / day, inclusive.
[0092] In certain embodiments, compositions of the disclosure comprising dactinomycin are administered at about 1 μg / kg / day, 2 μg / kg / day, 3 μg / kg / day, 4 μg / kg / day, 5 μg / kg / day, 6 μg / kg / day, 7 μg / kg / day, 8 μg / kg / day, 9 μg / kg / day, 10 μg / kg / day, 11 μg / kg / day, 12 μg / kg / day, 13 μg / kg / day, 14 μg / kg / day, 15 μg / kg / day The composition may be administered in a therapeutically effective amount of 10 μg / kg / day, 16 μg / kg / day, 17 μg / kg / day, 18 μg / kg / day, 19 μg / kg / day, 20 μg / kg / day, 21 μg / kg / day, 22 μg / kg / day, 23 μg / kg / day, 24 μg / kg / day, 25 μg / kg / day, 26 μg / kg / day, 27 μg / kg / day, 28 μg / kg / day, 29 μg / kg / day, or 30 μg / kg / day.
[0093] Compositions of the present disclosure comprising dactinomycin, e.g., compositions comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, may be administered at a therapeutically effective amount of the composition of about 5 μg / kg / day to about 15 μg / kg / day. In certain embodiments, compositions of the present disclosure comprising dactinomycin may be administered at a therapeutically effective amount of the composition of 5 μg / kg / day to 15 μg / kg / day. In certain embodiments, compositions of the present disclosure comprising dactinomycin may be administered at a therapeutically effective amount of the composition of about 12.5 μg / kg / day. In certain embodiments, compositions of the present disclosure comprising dactinomycin may be administered at a therapeutically effective amount of the composition of 12.5 μg / kg / day.
[0094] The disclosed compositions comprising dactinomycin, i.e., compositions comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, can be administered once a day. In certain embodiments, the disclosed compositions comprising dactinomycin can be administered twice a day.
[0095] The composition of the present disclosure that includes dactinomycin, for example, a composition that includes a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, can be administered twice a week.In certain embodiments, the composition of the present disclosure that includes dactinomycin can be administered once a week.In certain embodiments, the composition of the present disclosure that includes dactinomycin can be administered once every two weeks.
[0096] The total dosage administered over the course of treatment will depend on the amount administered per dose, the frequency of administration, and / or the length of treatment.
[0097] For example, if the amount of the composition administered is 10 μg / kg / day, the dosing frequency is once daily, and the length of treatment is one week, then the total dose would be 70 μg / kg.
[0098] For example, if the amount of the composition administered is 10 μg / kg / day, the dosing frequency is twice a week (e.g., on days 1 and 4), and the length of treatment is one week, then two doses of 35 μg / kg would be delivered during the week, for a total dose of 70 μg / kg.
[0099] For example, if the amount of the composition administered is 10 μg / kg / day, the dosing frequency is once a week, and the length of treatment is one week, then 70 μg / kg would be delivered once during the week, for a total dose of 70 μg / kg.
[0100] For example, if the amount of the composition administered is 10 μg / kg / day, the dosing frequency is once every two weeks, and the length of treatment is two weeks, then a total dose would be 140 μg / kg, delivered once during the two week period.
[0101] The determination of the total dosage to be administered to a subject is within the routine level of one of ordinary skill in the art.
[0102] The composition of the present disclosure comprising dactinomycin, for example, a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, may be administered for at least one cycle. In certain embodiments, the composition of the present disclosure comprising dactinomycin may be administered for at least two cycles. In one aspect of the present disclosure, one cycle may include treatment with the composition of the present disclosure for five consecutive days. In one embodiment, one cycle may include treatment with the composition of the present disclosure every day, twice a week, once a week, or once every two weeks.
[0103] In certain embodiments, the treatment further comprises a drug-free period of 1, 2, 3, 4, or more weeks between administrations and / or treatment cycles. In one embodiment, the drug-free period between two consecutive treatment cycles can be at least 2 weeks. In one embodiment, the drug-free period between two consecutive treatment cycles can be at least 4 weeks.
[0104] The method of the present disclosure may further comprise administering a blood transfusion to the subject. In certain embodiments, the composition of the present disclosure comprising dactinomycin, for example, a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, and the blood transfusion may be administered simultaneously. Alternatively, the composition of the present disclosure comprising dactinomycin and the blood transfusion may be administered sequentially. In certain embodiments, the composition of the present disclosure comprising dactinomycin may be administered prior to the blood transfusion. For example, a cycle of administration of the composition comprising dactinomycin may be completed, and the blood transfusion may be administered after a cycle of dactinomycin therapy or between two cycles of dactinomycin therapy. In certain embodiments, the blood transfusion may be administered after at least one cycle of treatment with the composition of the present disclosure comprising dactinomycin.
[0105] A subject of the present disclosure may suffer from mucositis before or after initiation of treatment with dactinomycin. A subject of the present disclosure may be predisposed to or at risk for developing mucositis. In certain embodiments in which a subject already has or may develop mucositis, a therapeutically effective amount of dactinomycin or a composition comprising a therapeutically effective amount of dactinomycin may be an amount sufficient to treat cancer (e.g., AML, or NPM1-mutated AML) without inducing or worsening mucositis in the subject.
[0106] In certain embodiments in which a subject already has or is likely to develop mucositis, a therapeutically effective amount of dactinomycin or a composition comprising a therapeutically effective amount of dactinomycin may be an amount sufficient to treat myelodysplastic syndrome (MDS) without inducing or worsening mucositis in the subject.
[0107] In certain embodiments in which a subject may develop or be susceptible to mucositis, the methods of the disclosure include administering combination therapy to the subject with one or more anti-inflammatory and / or antioxidant agents against symptoms of mucositis.
[0108] In certain embodiments in which the subject already has mucositis, the methods of the present disclosure include pretreating the subject with one or more anti-inflammatory and / or antioxidant agents against symptoms of mucositis prior to administering any of the compositions described herein.
[0109] According to the methods of the present disclosure, compositions of the present disclosure comprising dactinomycin may be administered to subjects with newly diagnosed and / or previously untreated AML as a desirable front-line therapy. In certain embodiments, the subject may be unfit for intensive chemotherapy. In certain embodiments, the subject may be at least 50 years old. In certain embodiments, the subject may be at least 60 years old. In certain embodiments, the subject may be at least 70 years old. In certain embodiments, subjects who may be unfit for intensive chemotherapy include, but are not limited to, subjects who may have an immune system deficiency, a blood disorder, an intestinal disorder, or an infection.
[0110] According to the methods of the present disclosure, the subject has not responded to another cancer therapy prior to administration of the dactinomycin composition of the present disclosure. In certain embodiments, the other cancer therapy includes azacytidine. In certain embodiments, the subject may experience a relapse following the other cancer therapy. In certain embodiments, the subject may experience remission after treatment with any of the dactinomycin compositions of the present disclosure. In certain embodiments, the term remission includes morphological remission and / or molecular remission.
[0111] In certain embodiments, the therapeutically effective amount of dactinomycin encapsulated in the nanoparticles has a C of 1 ng / mL to 30 ng / mL, inclusive. max For example, a therapeutically effective amount of dactinomycin encapsulated in nanoparticles may result in a C of about 1 ng / mL, 2 ng / mL, 3 ng / mL, 4 ng / mL, 5 ng / mL, 6 ng / mL, 7 ng / mL, 8 ng / mL, 9 ng / mL, 10 ng / mL, 11 ng / mL, 12 ng / mL, 13 ng / mL, 14 ng / mL, 15 ng / mL, 16 ng / mL, 17 ng / mL, 18 ng / mL, 19 ng / mL, 20 ng / mL, 21 ng / mL, 22 ng / mL, 23 ng / mL, 24 ng / mL, 25 ng / mL, 26 ng / mL, 27 ng / mL, 28 ng / mL, 29 ng / mL, or 30 ng / mL. max results.
[0112] In certain embodiments, the therapeutically effective amount of dactinomycin encapsulated in and / or associated with the nanoparticles has a C of 1 ng / mL to 20 ng / mL, inclusive. max results.
[0113] In certain embodiments, the therapeutically effective amount of dactinomycin encapsulated in and / or associated with the nanoparticles is between 10 ng / mL and 15 ng / mL.
[0114] In certain embodiments, the therapeutically effective amount of dactinomycin encapsulated in and / or associated with the nanoparticles has an AUC ∞ In one embodiment, the therapeutically effective amount of dactinomycin encapsulated in and / or associated with the nanoparticles has an AUC of about 0.05 to about 1.0 mg min / L. ∞ results.
[0115] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin, wherein the dactinomycin is encapsulated in and / or associated with nanoparticles, and further comprising a therapeutically effective amount of one or more additional chemotherapeutic agents, wherein the chemotherapeutic agents are selected from the group consisting of topoisomerase inhibitors, platinum-based therapeutic agents, anthracycline antibiotics, taxanes, tyrosine kinase inhibitors, nucleoside analogs, FLT3 inhibitors, and hypermethylation inhibitors, and wherein the chemotherapeutic agents are encapsulated in and / or associated with nanoparticles.
[0116] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin, wherein the dactinomycin is encapsulated in and / or associated with nanoparticles, and further comprising a therapeutically effective amount of one or more additional chemotherapeutic agents, wherein the chemotherapeutic agents are selected from the group consisting of a topoisomerase inhibitor, a platinum-based therapeutic agent, an anthracycline antibiotic, a taxane, a tyrosine kinase inhibitor, a nucleoside analog, an FLT3 inhibitor, and a hypermethylation inhibitor, wherein the chemotherapeutic agents are encapsulated in and / or associated with the nanoparticles, wherein the topoisomerase inhibitor can include etoposide, the platinum-based therapeutic agent can include cisplatin, and the anthracycline can include daunomycin, a cytochrome P450 inhibitor ... the taxanes may include paclitaxel or docetaxel; the tyrosine kinase inhibitors may include imatinib; the nucleoside analogs may include cytarabine, gemcitabine, or capecitabine; the FLT3 inhibitors may include Rydapt® (midostaurin), sorafenib, lestaurtinib, quizartinib, ponatinib, crenolanib, or gilteritinib; and / or the hypermethylation inhibitors may include azacitidine, decitabine, and zebularine.
[0117] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin, wherein the dactinomycin is encapsulated in and / or associated with a nanoparticle, and further comprising a therapeutically effective amount of a chemotherapeutic agent, wherein the chemotherapeutic agent is selected from the group consisting of a topoisomerase inhibitor, a platinum-based therapeutic agent, an anthracycline antibiotic, a taxane, a tyrosine kinase inhibitor, a nucleoside analog, an FLT3 inhibitor, and a hypermethylation inhibitor, wherein the molar ratio of the topoisomerase inhibitor, platinum-based therapeutic agent, anthracycline antibiotic, taxane, tyrosine kinase inhibitor, or nucleoside analog to dactinomycin is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, or any ratio therebetween. In certain embodiments, the molar ratio is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, or any ratio in between. In certain embodiments, the molar ratio is 7:1, 6:1, 5:1, 4:1, 3:1, or any ratio in between. In certain embodiments, the molar ratio is about 5:1. In certain embodiments, the molar ratio is 5:1.
[0118] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin and etoposide, wherein the dactinomycin and etoposide are encapsulated in and / or associated with nanoparticles, and the therapeutically effective amount of etoposide is less than 50 μg / mL C max In certain embodiments, the therapeutically effective amount of etoposide encapsulated in and / or associated with the nanoparticles has a C of between 1 and 50 μg / mL, inclusive. max results.
[0119] In certain embodiments, the therapeutically effective amount of etoposide encapsulated in and / or associated with the nanoparticles is between 30-45 mg / kg / day.
[0120] In certain embodiments, a therapeutically effective amount of etoposide encapsulated in and / or associated with a nanoparticle has an AUC of about 50 to about 60 μg·hr / mL / hr.∞ results.
[0121] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin and etoposide, the dactinomycin and etoposide being encapsulated in nanoparticles, and the molar ratio of etoposide to dactinomycin is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, or any ratio therebetween. In certain embodiments, the molar ratio is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, or any ratio therebetween. In certain embodiments, the molar ratio is 7:1, 6:1, 5:1, 4:1, 3:1, or any ratio therebetween. In certain embodiments, the molar ratio is about 5: 1. In certain embodiments, the molar ratio is 5: 1.
[0122] The present disclosure provides a method for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, such as a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles. In certain embodiments, the cancer is acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), colorectal cancer, neuroendocrine cancer, esophageal cancer, or gastrointestinal stromal tumor (GIST). In one embodiment, the cancer is acute myeloid leukemia (AML). In a preferred embodiment, the cancer is NPM1-mutated AML.
[0123] The present disclosure provides a method for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, wherein the composition is administered once a week. In certain embodiments, the composition is administered twice a week. In certain embodiments, the composition is administered once every two weeks. In certain embodiments, the composition is administered once a month.
[0124] The present disclosure provides a method for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, such as a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, wherein the composition is administered once a week, twice a week, once every two weeks, or once a month, and the composition is administered again after a rest period of 1, 2, 3, 4, or more weeks. In one embodiment, the rest period between two consecutive treatment cycles can be at least 2 weeks. In one embodiment, the rest period between two consecutive treatment cycles can be at least 4 weeks.
[0125] The present disclosure provides a method for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, and further comprising administering to the subject a therapeutically effective amount of an anti-inflammatory agent, an antioxidant, or a combination thereof. In certain embodiments, the anti-inflammatory agent includes pentoxifylline and / or NSAIDs. In certain embodiments, the antioxidant includes vitamin C and / or retinoic acid (e.g., all-trans-retinoic acid). In certain embodiments, the anti-inflammatory agent includes pentoxifylline and / or NSAIDs, and the antioxidant includes vitamin C or retinoic acid (e.g., all-trans-retinoic acid).
[0126] The present disclosure provides methods for treating myelodysplastic syndromes (MDS) and / or methods for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the method further comprising administering to the subject a therapeutically effective amount of an anti-inflammatory agent, an antioxidant, or a combination thereof, wherein the molar ratio of the anti-inflammatory agent, antioxidant, or combination thereof to dactinomycin is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, or any ratio therebetween.
[0127] The present disclosure relates to a method for treating myelodysplastic syndrome (MDS) and / or a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the method further comprising administering to the subject a therapeutically effective amount of an anti-inflammatory agent, an antioxidant, or a combination thereof, the composition and (a) an anti-inflammatory agent, (b) an antioxidant, and (c) a combination of the anti-inflammatory agent and the antioxidant; The method is provided wherein the dactinomycin and the anti-inflammatory agent, the antioxidant, or a combination thereof are administered simultaneously.
[0128] The present disclosure relates to a method for treating myelodysplastic syndrome (MDS) and / or a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the method further comprising administering to the subject a therapeutically effective amount of an anti-inflammatory agent, an antioxidant, or a combination thereof, the composition and (a) an anti-inflammatory agent, (b) an antioxidant, and (c) a combination of the anti-inflammatory agent and the antioxidant; The method further comprises administering the dactinomycin and the anti-inflammatory agent, the antioxidant, or a combination thereof, sequentially.
[0129] The present disclosure provides methods for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of any composition described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, wherein the composition further comprises a pharma- ceutically acceptable carrier.
[0130] The present disclosure provides a method for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, for example, a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, wherein the composition further comprises a pharma- ceutically acceptable carrier, and the composition is administered systemically. In certain embodiments, the composition is administered intravenously. In certain embodiments, the composition is administered by injection.
[0131] The present disclosure provides a method for treating myelodysplastic syndrome (MDS) and / or a method for treating cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of any composition described herein, for example a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, wherein the composition further comprises a pharma- ceutically acceptable carrier, and the composition is administered orally.In certain embodiments, the composition is in the form of a tablet.In certain embodiments, the composition is in the form of a capsule.
[0132] The present disclosure provides a method for treating myelodysplastic syndrome (MDS) and / or a method for treating cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of any composition described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the method further comprising administering to the subject a blood transfusion. In certain embodiments, the composition and the blood transfusion are administered simultaneously. In certain embodiments, the composition and the blood transfusion are administered sequentially. In certain embodiments, the composition is administered prior to the blood transfusion. In certain embodiments, the blood transfusion is administered after at least one cycle of treatment with the composition.
[0133] The present disclosure provides a method for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, wherein the subject has mucositis. In one embodiment, the treatment further comprises treatment with at least one additional chemotherapeutic agent selected from the group consisting of a topoisomerase inhibitor, a platinum-based therapeutic agent, an anthracycline antibiotic, a taxane, a tyrosine kinase inhibitor, a nucleoside analog, an FLT3 inhibitor, and a hypermethylation inhibitor.
[0134] The present disclosure provides a method for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, wherein the subject may develop mucositis or is susceptible to mucositis. In one embodiment, the treatment further comprises treatment with at least one additional chemotherapeutic agent selected from the group consisting of topoisomerase inhibitors, platinum-based therapeutic agents, anthracycline antibiotics, taxanes, tyrosine kinase inhibitors, nucleoside analogs, FLT3 inhibitors, and hypermethylation inhibitors.
[0135] The present disclosure provides a method for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, wherein the subject is at least 50 years of age. In certain embodiments, the subject is at least 60 years of age. In certain embodiments, the subject is at least 70 years of age.
[0136] The present disclosure provides a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, wherein the subject has not responded to another cancer therapy prior to administration of the composition. In certain embodiments, the other cancer therapy is azacitidine.
[0137] The present disclosure provides a method for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, wherein the subject has relapsed after other cancer therapy. In certain embodiments, the other cancer therapy is azacitidine. In certain embodiments, the remission is a morphological remission. In certain embodiments, the remission is a molecular remission.
[0138] The present disclosure provides methods for treating myelodysplastic syndromes (MDS) and / or cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the method further comprising administering a therapeutically effective amount of one or more additional chemotherapeutic agents selected from the group consisting of topoisomerase inhibitors, platinum-based therapeutic agents, anthracycline antibiotics, taxanes, tyrosine kinase inhibitors, nucleoside analogs, FLT3 inhibitors, and hypermethylation inhibitors.
[0139] In certain embodiments, the platinum-based therapeutic agent includes cisplatin.
[0140] In certain embodiments, the anthracycline includes daunorubicin, doxorubicin, epirubicin, or idarubicin.
[0141] In certain embodiments, the taxane includes paclitaxel or docetaxel.
[0142] In certain embodiments, the nucleoside analog includes cytarabine, gemcitabine, or capecitabine.
[0143] In certain embodiments, FLT3 inhibitors include Rydapt® (midostaurin), sorafenib, lestaurtinib, quizartinib, ponatinib, crenolanib, or gilteritinib.
[0144] In certain embodiments, hypermethylation inhibitors include azacytidine, decitabine, and zebularine.
[0145] The present disclosure relates to a method for treating myelodysplastic syndrome (MDS) and / or a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the method further comprising administering a therapeutically effective amount of at least one additional chemotherapeutic agent, the chemotherapeutic agent being a topoisomerase inhibitor, a platinum-based therapeutic agent, an anthracycline antibiotic, a taxane, a tyrosine kinase inhibitor, The method provides a method for treating a dyslipidemia, comprising administering to a subject a therapeutic agent selected from the group consisting of a nucleoside analog, an FLT3 inhibitor, and a hypermethylation inhibitor, wherein the molar ratio of the topoisomerase inhibitor, platinum-based therapeutic agent, anthracycline antibiotic, taxane, tyrosine kinase inhibitor, nucleoside analog, FLT3 inhibitor, or hypermethylation inhibitor to dactinomycin is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, or any ratio therebetween. In certain embodiments, the molar ratio is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, or any ratio therebetween. In certain embodiments, the molar ratio is 7:1, 6:1, 5:1, 4:1, 3:1, or any ratio therebetween. In certain embodiments, the molar ratio is about 5:1. In certain embodiments, the molar ratio is 5:1.
[0146] The present disclosure provides methods for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of any of the compositions described herein, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the method further comprising administering to the subject retinoic acid (e.g., all-trans-retinoic acid), valproic acid, a histone deacetylase inhibitor, a proteasome inhibitor, a farnesyltransferase inhibitor, a p53 stabilizer, or any combination thereof.
[0147] The present disclosure provides methods for treating myelodysplastic syndrome (MDS) and / or cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a composition comprising dactinomycin, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles.
[0148] The present disclosure provides compositions and methods for the treatment of AML, particularly NPM1-mutated AML, that address the underlying pathology in addition to the clinical symptoms of AML. (Dohner, H. et al. N. Engl. J. Med. 2015, 373:1136-1152).
[0149] The present disclosure provides a method for treating acute myeloid leukemia (AML) in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of a composition comprising dactinomycin, for example a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, in a preferred method, the AML is NPM1-mutated AML. In certain embodiments, the NPM1-mutated AML does not have FLT3 internal tandem duplication repeats.
[0150] According to the methods of the present disclosure, the therapeutically effective amount of the composition is 1-30 μg / kg / day (endpoints included) or 1-20 μg / kg / day (endpoints included). Low doses are effective over long periods. For example, a dose of 1 μg / kg / day can be used for long-term daily administration and / or maintenance administration to prevent relapse. High doses can be used safely over short periods. For example, 30 μg / kg / day can be used for one day followed by a dose reduction or treatment-free period, e.g., a two week treatment-free period between one-day treatment cycles. Alternatively, a high dose can be used to rapidly increase or spike plasma levels above the minimum effective threshold and continue the next day or with a treatment-free period at a low dose to maintain plasma concentration of dactinomycin. In certain embodiments of the methods of the present disclosure, the therapeutically effective amount of the composition is about 5 μg / kg / day to about 15 μg / kg / day, or 5 μg / kg / day to 15 μg / kg / day. Alternatively, the therapeutically effective amount of the composition is about or is 12.5 μg / kg / day. The therapeutically effective amount of the composition may be administered once a day or at least once a day, twice a week, once a week, or once every two weeks.
[0151] According to the methods of the present disclosure, compositions comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles may be administered to subjects with newly diagnosed and / or previously untreated AML who are ineligible for intensive chemotherapy or who are elderly (i.e., age 60 or older) as a desirable front-line therapy. Subjects who may be ineligible for intensive chemotherapy include, but are not limited to, subjects with compromised immune systems, blood disorders, intestinal disorders, or infections.
[0152] According to the methods of the present disclosure, a subject treated with a dactinomycin composition, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, may subsequently undergo remission, the term remission as used herein including morphological and / or molecular remission.
[0153] Any of the methods of the disclosure may further include administering to the subject a retinoic acid (e.g., all-trans-retinoic acid), valproic acid, a histone deacetylase inhibitor, a proteasome inhibitor, a farnesyltransferase inhibitor, a p53 stabilizer, or any combination thereof.
[0154] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin, for example, a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, wherein the therapeutically effective amount of dactinomycin is about 15 μg / kg / day or is 15 μg / kg / day.
[0155] The present disclosure provides a method for treating myelodysplastic syndrome (MDS) and / or a method for treating cancer in a subject in need of such treatment, comprising administering to the subject a composition comprising a therapeutically effective amount of dactinomycin, e.g., a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, wherein the therapeutically effective amount of dactinomycin is about 15 μg / kg / day or is 15 μg / kg / day. [Brief description of the drawings]
[0156] [Figure 1A] Figures 1A-1B are graphs showing the systemic concentration of dactinomycin over time. The data for these graphs are from 21 patients aged 16-53 years who received dactinomycin at 1 mg / m2 (27 μg / kg). (See Hill, C. R. et al. Clin. Pharmacokinet. (2014) 53:741-751; and Walsh, C. et al. Br J Clin Pharmacol (2016) 81:989-998.) [Figure 1B] Same as above. [Diagram 2] Figure 2 is a pair of graphs showing Cmax (ng / mL) (graph A) and AUC0-6time (mg / L·min) (graph B) as a function of dactinomycin dose (mg / m2). [Diagram 3]Figure 3 is a series of photographs showing nucleolar disintegration and apoptosis induced by Act-D in the NPM1-mutant cell line OCI / AML3. NPM1 = nucleophosmin, DAPI = 4',6-diamidino-2-phenylindole - a fluorescent stain that binds tightly to AT-rich regions of DNA. [Figure 4] Figure 4 is a series of photographs of Western blots (cells taken for biopsy after treatment) showing activation of p53 by administration of dactinomycin to NPM1-mutated AML tumor cells contacted in vitro or in vivo from patient MM (the patient was a 60-year-old woman with pancytopenia and extensive blast infiltration of the bone marrow, diagnosed with NPM1-mutated AML, ineligible for chemotherapy due to low left ventricular ejection fraction due to a history of myocardial infarction, initially treated with azacitidine but the disease progressed, so she was treated with actinomycin D (no cardiac toxicity) at 12.5 μg / kg for 2 cycles on consecutive 5 days). [Diagram 5] Figure 5 is a chart showing sequencing by TruSight Myeloid Panel. - Mutant genes (*). Patient MMNMP1, IDH2, and STAG2 mutations were not detected after Act-D. [Figure 6A] Figures 6A-B are a series of photographs showing hematoxylin-eosin staining (HE staining) of bone marrow biopsies at the time of relapse before dactinomycin treatment. PGM1 = phosphoglucomutase 1, MPO = myeloperoxidase. [Figure 6B] Same as above. [Figure 7] FIG. 7 is a photograph of a computed tomography (CT) scan showing interstitial pneumonia in a subject administered dactinomycin at 15 μg / kg for 5 days. [Figure 8] FIG. 8 is a pair of graphs showing hematological recovery after one cycle of dactinomycin treatment. [Figure 9A] Figures 9A-9B are a pair of photographs showing bone marrow (BM) examination results before and after treatment with dactinomycin alone. BM examination after treatment with ActD showed a significant reduction in infiltration of leukemic blast cells and partial recovery of normal hematopoiesis. [Figure 9B] Same as above. [Figure 10] Figure 10 is a pair of graphs showing homologous recovery with treatment with dactinomycin and low dose cytarabine (LDAC). Complete blood count (CBC) d=46, white blood cells 4130 / mm3, neutrophil percentage (N=66%), hemoglobin (Hb)=7.7g / dL, platelet (PLT) count 192.000 / mm3. Erythropoietin (EPO) dose=17.8mUl / ml (abnormal response). Patient started treatment with darbepoetin alfa. [Figure 11] FIG. 11 is a series of flow cytometry plots showing clearance of leukemic blast cells. [Figure 12] FIG. 12 is a pair of photographs showing bone marrow (BM) results before and after treatment with dactinomycin and LDAC (right), demonstrating complete hematologic remission with recovery of normal triple-line hematopoiesis. [Figure 13] FIG. 13 is a series of photographs showing bone marrow biopsy results following treatment with dactinomycin and LDAC. [Figure 14] Figure 14 is a photograph showing restoration of erythropoiesis. GlyC = serine hydroxymethyltransferase, cytoplasmic. [Figure 15] FIG. 15 is a graph showing nanoparticle size distribution of a composition prepared with dactinomycin and Resomer® R 203 H (PLA). [Figure 16] FIG. 16 is a graph showing nanoparticle size distribution of a composition prepared with dactinomycin and Resomer® 100 DL mPEG 5000 (25% mPEG) (PLA-mPEG). [Figure 17] FIG. 17 is a graph showing the nanoparticle size distribution of a composition prepared with dactinomycin and Resomer® R 203 H (PLA) after the composition was passed through a 200 nm cellulose acetate membrane filter without surfactant (lower line). [Figure 18]FIG. 18 is a graph showing the nanoparticle size distribution of a composition prepared with dactinomycin and Resomer® 100 DL mPEG 5000 (25% mPEG) (PLA-mPEG) after the composition was passed through a 200 nm cellulose acetate membrane filter without surfactant (top line). [Figure 19] FIG. 19 is a graph showing the nanoparticle size distribution of a composition prepared with dactinomycin and Resomer® R 202 S after evaluating the stability of the composition under various conditions. (T0= [Figure 20] 20-21 are graphs showing the nanoparticle size distribution of compositions prepared with dactinomycin and Resomer® R 203 H after evaluating the stability of the compositions under various conditions. [Figure 21] Same as above. [Figure 22] 22-23 are graphs showing the nanoparticle size distribution of a composition prepared using dactinomycin and Resomer® 100DL mPEG 5000 (25%) after evaluating the stability of the composition under various conditions. [Figure 23] Same as above. [Figure 24] 24-25 are graphs showing the nanoparticle size distribution of a composition prepared using dactinomycin and Resomer® 5050 DLG mPEG 5000 (35%) after evaluating the stability of the composition under various conditions. [Diagram 25] Same as above. [Figure 26] FIG. 26 is a graph showing nanoparticle size distribution of a composition prepared with dactinomycin and PEGylated poly D,L lactide after evaluating the stability of the composition under various conditions. [Figure 27]FIG. 27 is a series of graphs showing the in vitro release of free dactinomycin compared to four compositions prepared with dactinomycin and Resomer® R 202 S, Resomer® R 203 H, Resomer® 100DL mPEG 5000 (25%), and Resomer® 5050DLG mPEG 5000 (35%). [Figure 28A] Figures 28A-D are a series of graphs showing the in vitro release of dactinomycin from four compositions of the present application after two months of storage at 4°C. (Figure 28A: 100DL mPEG 5000 (25%), Figure 28B: Resomer® 5050DLG mPEG 5000 (35%), Figure 28C: Resomer® R 203 H, Figure 28D: Resomer® R 202 S). [Figure 28B] Same as above. [Figure 28C] Same as above. [Figure 28D] Same as above. [Figure 29] FIG. 29 is a series of graphs showing the effect over time on rat body weight following in vivo treatment with free dactinomycin compared to four compositions of the present application (Resomer® R 202 S, Resomer® R 203 H, Resomer® 100DL mPEG 5000 (25%), Resomer® 5050DLG mPEG 5000 (35%)). [Diagram 30] FIG. 30 is a series of graphs showing the effect on CMAX over time following in vivo treatment with free dactinomycin compared to four compositions of the present application (Resomer® R 202 S, Resomer® R 203 H, Resomer® 100DL mPEG 5000 (25%), Resomer® 5050DLG mPEG 5000 (35%)). [Diagram 31]FIG. 31 is a series of graphs showing the effect on CMAX over time following in vivo treatment with free dactinomycin compared to four compositions of the present application (Resomer® R 202 S, Resomer® R 203 H, Resomer® 100DL mPEG 5000 (25%), Resomer® 5050DLG mPEG 5000 (35%)). [Diagram 32] FIG. 32 is a series of graphs showing the effect over time on rat body weight following in vivo treatment with free dactinomycin compared to four compositions of the present application (Resomer® R 202 S, Resomer® R 203 H, Resomer® 100DL mPEG 5000 (25%), Resomer® 5050DLG mPEG 5000 (35%)). [Diagram 33] FIG. 33 is a series of graphs showing the time course of viability following in vivo treatment with free dactinomycin compared to four compositions of the present application (Resomer® R 202 S, Resomer® R 203 H, Resomer® 100DL mPEG 5000 (25%), Resomer® 5050DLG mPEG 5000 (35%)). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0157] NPM1-mutated acute myeloid leukemia (AML) is a unique leukemia that accounts for one-third of AML cases in adults. NPM1 is a protein crucial for normal nucleolar integrity and function. Due to low levels of non-mutated NPM1 in this disease (due to haploinsufficiency and cytoplasmic retention of non-mutated NPM1 by NPM1 mutations), the nucleoli of NPM1-mutated AML cells may be susceptible to drugs that induce a nucleolar stress response. The tumor suppressor p53 is frequently inactivated in cancers, either by downregulation of the protein or loss-of-function mutations. Thus, stabilizing p53 can treat cancers that harbor wild-type (WT) p53. Herein, p53 was stabilized using the SIRT1 inhibitor Tenovin-1 and the polo-like kinase 1 (Plk1) inhibitor BI2536. (See Chen, L et al. Cell Cycle 2016,15(6):840-849). Both p53-dependent and p53-independent responses to nucleolar stress have been reported. Importantly, the p53-mediated nucleolar stress response is preserved in NPM1-mutated AML, because NPM1-mutated AML cells do not harbor p53 mutations or deletions.
[0158] Among potentially active agents, the present disclosure focuses on dactinomycin because it induces nucleolar stress by disrupting ribosome biogenesis through inhibition of RNA polymerase I. Dactinomycin has shown activity in Wilms tumor and several other tumors, whereas the present disclosure describes the first studies using dactinomycin in AML.
[0159] Additionally, the disclosure provides a method of treating myelodysplastic syndrome (MDS) comprising administering a composition comprising dactinomycin.
[0160] The present disclosure also provides a method of treating cancer comprising administering a composition comprising dactinomycin. In certain embodiments, the cancer can be acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), colon cancer, neuroendocrine cancer, esophageal cancer, or gastrointestinal stromal tumor (GIST). In certain embodiments, the cancer can be acute myeloid leukemia (AML). In certain embodiments, the AML can be NPM1-mutated AML or wild-type AML. In certain embodiments, the AML can be NPM1-mutated AML.
[0161] According to the methods of the present disclosure, compositions of the present disclosure comprising dactinomycin may be administered as a desirable frontline therapy to subjects with newly diagnosed and / or previously untreated cancer who are ineligible for intensive chemotherapy or who are elderly (i.e., age 60 or older). Subjects who may be ineligible for intensive chemotherapy include, but are not limited to, subjects with compromised immune systems, blood disorders, intestinal disorders, or infections.
[0162] In certain embodiments of the present disclosure, dactinomycin compositions may be administered to subjects with newly diagnosed and / or previously untreated AML who are unsuitable for intensive chemotherapy or who are elderly (i.e., age 60 or older) as a desirable frontline therapy. Subjects who may be unsuitable for intensive chemotherapy include, but are not limited to, subjects with compromised immune systems, blood disorders, intestinal disorders, or infections.
[0163] Acute myeloid leukemia (AML) AML Acute myeloid leukemia (AML) is the most common name for a condition alternatively called acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, or acute nonlymphocytic leukemia. (See Falini, B. et al. "Cytoplasmic nucleo-phosmin in acute myelogenous leukemia with a normal karyo-type" N. Engl. J. Med. 2005;352:254-266; Cancer Genome Atlas Research Network. "Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia" N. Engl. J. Med. 2013;368:2059-2074).
[0164] AML initially develops in the bone marrow. However, AML cells quickly progress into the blood. Once present in a subject's blood, the cancerous cells can spread to any part of the body, including but not limited to lymph nodes, liver, spleen, central nervous system (brain and / or spinal cord), skin, and / or testicles.
[0165] In acute forms of leukemia, the cancer cells are immature blood cells with stem cell-like properties that under normal conditions rapidly divide to provide many blood cell types. When these cells undergo oncogenic transformation, the rapid division gives rise to cancer cells at a faster rate than cancers affecting mature and / or terminally differentiated cell types.
[0166] In the myeloid form of leukemia, cancer cells transform from stem-like bone marrow cells that under normal conditions divide to produce cells that differentiate into red blood cells, white blood cells, and megakaryocytes that produce platelets. When these cells undergo oncogenic transformation, the immature bone marrow cells do not immediately divide to increase the number and / or proportion of red blood cells, white blood cells, and platelets that would normally then become circulating blood. As a result, under oncogenic conditions, bone marrow cells divide and aggregate in the bones, and the increased production of these cells competes with and interferes with the normal functioning source of healthy non-cancerous cells in the bone marrow. Furthermore, under oncogenic conditions, bone marrow cells do not produce enough red blood cells to carry normal levels of oxygen via the blood to one or more organs, do not produce enough white blood cells to mount an appropriate immune response to infection, and / or do not produce enough platelets to promote blood clotting.
[0167] The subject of the present disclosure may exhibit one or more risk factors for developing AML. Examples of risk factors include, but are not limited to, a personal and / or family history of cancer, increasing age, male gender, history of chemotherapy and / or radiation treatment, exposure to radiation (including survivors of nuclear reactor accidents), exposure to hazardous chemicals (including, for example, benzene), past or current smoking habits, exposure to secondhand smoke, personal history of other blood disorders (including, for example, myelodysplasia, polycythemia vera, and / or thrombocythemia), and genetic disorders (including, for example, Down's syndrome). The subject of the present disclosure may be of any gender, but genetically male subjects are at a higher risk of developing AML than genetically female subjects. The subject of the present disclosure may be of any age, but subjects at least 40 years old, at least 50 years old, at least 60 years old, at least 70 years old, at least 80 years old, or at least 90 years old are at a higher risk of developing AML than younger subjects.
[0168] Subjects of the present disclosure may present with one or more signs or symptoms of AML, including, but not limited to, fever, bone pain, lethargy and / or fatigue, shortness of breath, pale skin, frequent infections, easy bruising, abnormal bleeding (e.g., from the nose and gums, and / or from reduced or insufficient blood clotting).
[0169] According to the methods of the present disclosure, dactinomycin may be administered as a desirable frontline therapy to subjects with newly diagnosed and / or previously untreated AML who are ineligible for intensive chemotherapy or who are elderly (i.e., age 60 or older). Subjects who may be ineligible for intensive chemotherapy include, but are not limited to, subjects with compromised immune systems, blood disorders, intestinal disorders, or infections.
[0170] A subject of the present disclosure may have been treated for AML with another therapy and may have been resistant to that therapy or may not have seen any improvement as a result of that therapy. Thus, a subject of the present disclosure includes an individual who has failed one or more therapies prior to treatment with dactinomycin of the methods of the present disclosure.
[0171] Treating AML can result in partial or complete hematological remission. Complete hematological remission is defined as a reduction in leukemia cells to less than 5% of bone marrow cells as determined by morphological examination of bone marrow smears and / or bone marrow sections. Partial hematological remission is defined as a reduction in leukemia cells to more than 5% of bone marrow cells but less than the initial percentage of bone marrow cells as determined by morphological examination of bone marrow smears and / or bone marrow sections. The initial percentage of leukemia cells in bone marrow cells can be calculated at the time of diagnosis and / or at the start of treatment. The reduction in the initial percentage can be measured at any time during or after completion of treatment.
[0172] Furthermore, treating AML can reduce the size of cell proliferation area or cell proliferation zone, especially extramedullary leukemia mass. Preferably, after treatment, the size of cell proliferation area or cell proliferation zone is reduced by at least 5% compared to the size before treatment, more preferably by at least 10%, more preferably by at least 20%, more preferably by at least 30%, more preferably by at least 40%, more preferably by at least 50%, even more preferably by at least 50%, and most preferably by at least 75%. The size of cell proliferation area or cell proliferation zone can be measured by any reproducible measuring means. The size of cell proliferation area or cell proliferation zone can be measured as the diameter or width of cell proliferation area or cell proliferation zone.
[0173] Treating AML can reduce the number or percentage of cells with abnormal appearance or morphology (i.e., morphological regression). Preferably, after treatment, the number of cells with abnormal morphology is reduced by at least 5% compared to the size before treatment, more preferably by at least 10%, more preferably by at least 20%, more preferably by at least 30%, more preferably by at least 40%, more preferably by at least 50%, even more preferably by at least 50%, and most preferably by at least 75%. Abnormal cell appearance or morphology can be measured by any reproducible measuring means. Abnormal cell morphology can be measured using a microscope, for example, using an inverted tissue culture microscope. Abnormal cell morphology can take the form of nuclear pleomorphism.
[0174] NPM1-mutated acute myeloid leukemia (AML) NPM1-mutated acute myeloid leukemia (AML) is a unique leukemia that accounts for one-third of AML cases in adults. NPM1 is a protein that is crucial for normal nucleolar integrity and function. (See Falini, B. et al. "Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?" Blood Rev. 2011;25:247-254).
[0175] Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in older adults. It is characterized by the accumulation of CD5 / CD19 / CD23 positive B lymphocytes in the blood, bone marrow, lymph nodes, and spleen. The clinical course of the disease is highly variable, ranging from patients remaining asymptomatic for 10 years to those who require aggressive treatment soon after diagnosis.
[0176] Myelodysplastic syndromes (MDS) As used herein, the term "myelodysplastic syndromes (MDS)" and / or the like refers to a group of one or more disorders caused by incompletely formed or malfunctioning blood cells in the bone marrow.
[0177] In one embodiment, myelodysplastic syndromes (MDS) are a group of diverse bone marrow disorders that affect the red blood cells, white blood cells, and platelets in the bone marrow.
[0178] Progenitor stem cells may fail to mature and accumulate in the bone marrow, or may have a short life span, resulting in fewer than normal mature blood cells in the circulation.
[0179] The incidence of MDS is approximately 4 to 5 cases per 100,000 people, increasing to 20 to 50 cases per 100,000 people over the age of 60.
[0180] MDS progresses to acute myeloid leukemia (AML) in approximately 30% of affected cases.
[0181] As used herein, the term "symptom" is defined as an indication of a disease, illness, injury, or physical ill-being. A symptom is felt or noticed by the individual experiencing the symptom, but may not be readily noticeable by others. Others are defined as non-medical professionals.
[0182] As used herein, the term "symptom" is defined as something that indicates something is not well with the body, however a symptom is defined as something that can be seen by a doctor, nurse, or other medical professional.
[0183] As used herein, the term "adverse event" or "AE" refers to any untoward and unintended sign (including abnormal laboratory findings), symptom, or disease temporarily associated with the use of a medicinal product (investigational drug), which may or may not be considered related to a therapeutic or medical procedure. (See Common Terminology Criteria for Adverse Events v3.0 (CTCAE), published August 9, 2006.)
[0184] As used herein, the term "remission" refers to the reduction or disappearance of signs and symptoms of cancer. In partial remission, some (but not all) signs and symptoms of cancer have disappeared. In complete remission, all signs and symptoms of cancer have disappeared, although the cancer may still be present in the body. In one aspect, remission can be morphological in nature. In one aspect, remission can be molecular in nature. In one aspect, remission can be both morphological and molecular in nature.
[0185] As used herein, the term "cancer" refers to diseases involving abnormal cell proliferation with the potential to spread to other parts of the body. Non-limiting examples include hematopoietic and lymphoid tumors (acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL)), colon cancer, neuroendocrine cancer, esophageal cancer (Barrett's syndrome), gastrointestinal stromal tumor (GIST), bone marrow tumors, myelodysplastic syndromes, myeloproliferative disorders, lymph node tumors and lymphatic tumors, Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, or any metastasis thereof.
[0186] As used herein, the term "selective" means that an event tends to occur more frequently in one population than in another. The populations being compared can be cell populations. Preferably, the dactinomycin or dactinomycin composition of the present disclosure acts selectively on cancer or precancerous cells, but not on normal cells. Preferably, the dactinomycin or dactinomycin composition of the present disclosure acts selectively to modulate one molecular target (e.g., RNA / DNA chain elongation by inhibiting ribosome biogenesis) but does not significantly modulate another molecular target (e.g., cellular repair enzymes). Preferably, an event is selectively occurring in population A compared to population B if it occurs more than twice as frequently in population A compared to population B. An event is selectively occurring in population A if it occurs more than five times as frequently in population A. An event occurs preferentially if it occurs more than 10-fold more frequently in population A, more preferably more than 50-fold more frequently in population A compared to population B, even more preferably more than 100-fold more frequently, and most preferably more than 1000-fold more frequently. For example, cell death occurs preferentially in cancer cells if cell death occurs more than twice as frequently in cancer cells compared to normal cells.
[0187] The dactinomycin compositions of the present disclosure can modulate the activity of a molecular target (e.g., ribosome). Modulating refers to stimulating or inhibiting the activity of the molecular target. Preferably, the dactinomycin compositions of the present disclosure modulate the activity of a molecular target if they stimulate or inhibit the activity of the molecular target at least 2-fold compared to the activity of the molecular target under the same conditions, except that they do not contain the compound. More preferably, the dactinomycin compositions of the present disclosure modulate the activity of a molecular target if they stimulate or inhibit the activity of the molecular target at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, or at least 100-fold compared to the activity of the molecular target under the same conditions, except that they do not contain the compound. The activity of a molecular target can be measured by any reproducible means of measurement. The activity of a molecular target can be measured in vitro or in vivo. For example, the activity of a molecular target can be measured in vitro by an enzyme activity assay or a DNA binding assay, or the activity of a molecular target can be measured in vivo by assaying for the expression of a reporter gene.
[0188] Dactinomycin is a polypeptide antitumor antibiotic composed of two cyclic peptides linked to a phenoxazine derived from Streptomyces parvullus. Dactinomycin binds to DNA and inhibits RNA synthesis (transcription) by specifically interfering with the chain elongation of mRNA transcripts. Dactinomycin binds tightly but reversibly to DNA molecules. As a result of the inhibition of mRNA production, protein synthesis, ribosome biogenesis, and cell division are reduced after dactinomycin therapy. It has been hypothesized that dactinomycin inhibits cell division and thus inhibits the oncogenic cell division associated with AML in the bone marrow.
[0189] Dactinomycin is currently used as a highly effective chemotherapy agent approved for rare tumors occurring primarily in children (Wilms' tumor, rhabdomyosarcoma, gestational trophoblastic disease, Ewing's sarcoma, etc.) (see Osathanondh, R. et al. Cancer 1975;36:863-866; Burger K. et al. J. Biol. Chem. 2010;285:12416-12425). Thus, dactinomycin has a known risk profile.
[0190] The disclosed dactinomycin compositions and formulations may be used early to treat high-risk patients with CLL.
[0191] Dactinomycin is highly corrosive and can produce many adverse side effects, including tissue necrosis, and extravasation can occur days to weeks after administration at the injection site followed by mucositis, a severely painful blistering, inflammation, and ulceration of the mucous membranes lining the gastrointestinal tract, and is an adverse effect of chemotherapy and radiation therapy treatments for cancer and / or MDS.
[0192] Mucositis can be harmful and debilitating, preventing subjects being treated with dactinomycin from continuing or completing treatment. Mucositis occurring in the mouth, i.e., oral mucositis, is common and is a frequently debilitating complication of cancer and / or MDS treatment (e.g., treatment with dactinomycin).
[0193] Mucositis is a debilitating hazard in cancer treatment that can prevent subjects being treated with dactinomycin from continuing or completing treatment, and is problematic in many cases because subjects who discontinue or are unable to complete dactinomycin treatment may experience a recurrence of their cancer.
[0194] The onset of mucositis may be dose dependent, and administration of a controlled release dose of dactinomycin in the range of 10-20 μg / kg / day of any of the dactinomycin nanoparticle compositions of the present application can reduce the onset of mucositis while still maintaining efficacy in treating MDS and / or cancer (e.g., AML, etc.). In one embodiment, the onset of mucositis can be reduced by co-therapy with anti-inflammatory agents, antioxidants, and / or growth differentiation promoters.
[0195] Mucositis can also be alleviated by pretreatment with anti-inflammatory agents, such as pentoxifylline, NSAIDs, antioxidants (e.g., vitamin C and retinoic acid (e.g., all-trans-retinoic acid)), growth promoters (e.g., glutamine).
[0196] Additionally, mucositis can be alleviated by using a dosing regimen that provides a "drug holiday" between dosing periods. The drug holiday can be 1 week, 2 weeks, 3 weeks, or 4 weeks.
[0197] In one embodiment, the administration period of any of the dactinomycin nanoparticle compositions of the present application is once or twice over a one, two, or three week period.
[0198] In one embodiment, a typical dosing cycle includes mucositis pretreatment with an anti-inflammatory agent followed by one or two treatments with any of the nanoparticle compositions of the present application over one, two, or three weeks, followed by a drug-free period of one, two, three, four, five, or six weeks, followed by one or two treatments with any of the nanoparticle compositions of the present application over one, two, or three weeks.
[0199] Dactinomycin is also sometimes called 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-I)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide, ActD, actinomycin C1, actinomycin D, actinomycin iv, dactinomycin, dactinomycin, dactinomycin, dactinomycinum, or meractinomycin. Dactinomycin belongs to a class of organic compounds known as cyclic depsipeptides. Cyclic depsipeptides include naturally occurring and / or non-naturally occurring (i.e., synthetic) compounds that contain a sequence of amino acid residues and hydroxycarboxylic acid residues (usually alpha amino acids and alpha hydroxy acids) linked in a ring. The amino acid residues and hydroxycarboxylic acid residues of dactinomycin may alternate in a repeating pattern.
[0200] Pharmaceutical Compositions The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising one or more polymers, including but not limited to poly(lactic acid) (PLA), poly(butyric acid), poly(valeric acid), poly(caprolactone) (PCL), poly(hydroxybutyric acid), poly(lactide-co-caprolactone), poly(lactide-co-glycolide) (PLGA), polymethylcyanoacrylate, and polyanhydrides, poly(ortho)esters, or polyurethanes thereof, optionally further comprising polyethylene glycol (PEG) or polyethylene glycol methyl ether (mPEG), and / or any combination thereof.
[0201] The present disclosure provides compositions comprising blends, i.e., blends of one or more polymers selected from poly(lactic acid) (PLA), poly(butyric acid), poly(valeric acid), poly(caprolactone) (PCL), poly(hydroxybutyric acid), poly(lactide-co-caprolactone), poly(lactide-co-glycolide) (PLGA), polymethylcyanoacrylate, and polyanhydrides, poly(ortho)esters, or polyurethanes thereof.
[0202] The present disclosure also provides a composition comprising a blend, i.e., a blend of one or more polymers selected from poly(lactic acid) (PLA), poly(butyric acid), poly(valeric acid), poly(caprolactone) (PCL), poly(hydroxybutyric acid), poly(lactide-co-caprolactone), poly(lactide-co-glycolide) (PLGA), polymethylcyanoacrylate, and polyanhydrides, poly(ortho)esters, or polyurethanes thereof, wherein the polymer further comprises polyethylene glycol (PEG), polyethylene glycol methyl ether (mPEG), and / or any combination thereof.
[0203] One of ordinary skill in the art will recognize that by selecting different combinations of these polymers, the release profile and / or kinetics may be altered (e.g., increased or decreased). It is within the level of ordinary skill in the art to determine the appropriate combination of polymers to achieve the desired release rate.
[0204] Nanoparticles, as used herein, refer to particles having a size of about 1 to 500 nanometers (nm), for example, in one embodiment, about 100 nm to about 200 nm.
[0205] In one embodiment, compositions of the present disclosure include compositions comprising dactinomycin encapsulated in and / or associated with nanoparticles.
[0206] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising a polylactic acid (PLA) polymer. PLA is typically an amorphous (non-crystalline) biodegradable polymer that is a mixture of D and L enantiomers of lactic acid. PLA can also be used as a crystalline polymer when synthesized using only a single enantiomer of lactic acid.
[0207] In one embodiment, the present disclosure provides dactinomycin encapsulated in nanoparticles comprising PLA, the PLA having a molecular weight in the range of about 10,000 to about 24,000 Da, allowing for controlled release of the dactinomycin.
[0208] In one embodiment, the molecular weight of the PLA is from about 10,000 Da to about 18,000 Da.
[0209] In one embodiment, the molecular weight of the PLA is from about 18,000 Da to about 24,000 Da.
[0210] In one embodiment, the molecular weight of the PLA is about 10,000 Da to about 14,000 Da, 11,000 Da to about 15,000 Da, 12,000 Da to about 16,000 Da, 13,000 Da to about 17,000 Da, 14,000 Da to about 18,000 Da, 15,000 Da to about 19,000 Da, 16,000 Da to about 20,000 Da, 17,000 Da to about 21,000 Da, 18,000 Da to about 22,000 Da, 19,000 Da to about 23,000 Da, or 20,000 Da to about 24,000 Da.
[0211] In one embodiment, the molecular weight of the PLA is about 10,000 Da, about 11,000 Da, about 12,000 Da, about 13,000 Da, about 14,000 Da, about 15,000 Da, about 16,000 Da, about 17,000 Da, about 18,000 Da, about 19,000 Da, about 20,000 Da, about 21,000 Da, about 22,000 Da, about 23,000 Da, or about 24,000 Da.
[0212] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising PLA, the PLA being ester-terminated.
[0213] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising PLA, the PLA being acid-terminated, the ester-terminated form of PLA being more hydrophobic than the acid-terminated form of PLA, which is more hydrophilic.
[0214] In one embodiment, a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising ester-terminated PLA, degrades more slowly than dactinomycin encapsulated in nanoparticles containing acid-terminated PLA, resulting in a slower release of dactinomycin from the nanoparticles.
[0215] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising a poly(lactide-co-glycolide) (PLGA) polymer:
[0216] [ka]
[0217] In an aqueous environment, PLGA biodegrades by hydrolysis of the ester bonds.
[0218] The methyl side chains of PLA make the polymer more hydrophobic than PGA, In one embodiment, lactide-rich PLGA copolymers are less hydrophilic than less lactide-rich copolymers, so they absorb less water and degrade more slowly.
[0219] In one embodiment, higher molecular weight PLGA degrades more slowly than lower molecular weight PLGA.
[0220] In one embodiment, the present disclosure provides dactinomycin encapsulated in nanoparticles comprising PLGA, the PLGA having a molecular weight in the range of about 7,000 to about 54,000 Da, allowing for controlled release of the dactinomycin.
[0221] In one embodiment, the molecular weight of the PLGA is from about 7,000 Da to about 17,000 Da, 17,000 Da to about 27,000 Da, 27,000 Da to about 37,000 Da, 37,000 Da to about 47,000 Da, or 47,000 Da to about 54,000 Da.
[0222] In one embodiment, the molecular weight of the PLGA is from about 12,000 Da to about 22,000 Da, 22,000 Da to about 32,000 Da, 32,000 Da to about 42,000 Da, 42,000 Da to about 52,000 Da, or 44,000 Da to about 54,000 Da.
[0223] In one embodiment, the molecular weight of the PLGA is about 7,000 Da, about 8,000 Da, about 9,000 Da, about 10,000 Da, about 11,000 Da, about 12,000 Da, about 13,000 Da, about 14,000 Da, about 15,000 Da, about 16,000 Da, about 17,000 Da, about 18,000 Da, about 19,000 Da, about 20,000 Da, about 21,000 Da, about 22,000 Da, about 23,000 Da, about 24,000 Da, about 25,000 Da, about 26,000 Da, about 27,000 Da, about 28,000 Da, about 29,000 Da, about 30,000 Da, about 31,000 Da, about 32,000 Da, about 33,000 Da, about 34,000 Da, about 35,000 Da, about 36,000 Da, about 37,000 Da, about 38,000 Da, about 39,000 Da, about 40,000 Da, about 41,000 Da, about 42,000 Da, about 43,000 Da, about 44,000 Da, about 45,000 Da, about 46,000 Da, about 47,000 Da, about 48,000 Da, about 49,000 Da, about 50,000 Da, about 51,000 Da, about 52,000 Da, about 53,000 Da, about 54,000 Da, about 55,000 Da, about 56,000 Da, about 00 Da, about 31,000 Da, about 32,000 Da, about 33,000 Da, about 34,000 Da, about 35,000 Da, about 36,000 Da, about 37,000 Da, about 38,000 Da, about 39,000 Da, about 40,000 Da, about 41,000 Da, about 42,000 Da, about 43,000 Da, about 44,000 Da, about 45,000 Da, about 46,000 Da, about 47,000 Da, about 48,000 Da, about 49,000 Da, about 50,000 Da, about 51,000 Da, about 52,000 Da, about 53,000 Da, or about 54,000 Da.
[0224] In one embodiment, the disclosure provides dactinomycin encapsulated in nanoparticles comprising PLGA, wherein the PLGA has a molar ratio of lactic acid:glycolic acid of about 95:5, about 90:10, about 85:15, about 80:20, about 75:25, about 70:30, about 65:35, about 60:40, about 55:45, about 50:50, about 45:55, about 40:60, about 35:65, about 30:70, about 25:75, about 20:80, about 15:85, about 10:90, or about 5:95.
[0225] In one embodiment, the disclosure provides dactinomycin encapsulated in nanoparticles comprising PLGA, wherein the PLGA has a molar ratio of lactic acid:glycolic acid of about 50:50.
[0226] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising a polylactic acid (PLA) polymer, which can be synthesized with polyethylene glycol (PEG) or polyethylene glycol methyl ether (mPEG) to prepare diblock copolymers (PLA-PEG and PLA-mPEG) to allow for controlled release of dactinomycin.
[0227] In one embodiment, the PLA-mPEG copolymer can be prepared according to the following scheme:
[0228] [ka]
[0229] The hydrophilic PEG (and mPEG) moieties are oriented toward the surface of the nanoparticles and act as a barrier to reduce interactions with external molecules through steric and hydration repulsion. These compositions can have a longer half-life in the systemic circulation compared to unmodified nanoparticles (i.e., "non-PEGylated" or "non-mPEGylated" nanoparticles).
[0230] In one embodiment, drug release from PLA-PEG and PLA-mPEG nanoparticles occurs by diffusion. In one embodiment, drug release from PLA-PEG and PLA-mPEG nanoparticles occurs by polymer degradation. In one embodiment, drug release from PLA-PEG and PLA-mPEG nanoparticles occurs by both diffusion and polymer degradation.
[0231] The ratio of PEG or mPEG to PLGA can affect the clearance of the nanoparticles from the systemic circulation.
[0232] In one embodiment, the weight percentage of PEG or mPEG in the PLA-PEG or PLA-mPEG diblock copolymer is about 1 wt%, about 2 wt%, about 3 wt%, about 4 wt%, about 5 wt%, about 6 wt%, about 7 wt%, about 8 wt%, about 9 wt%, about 10 wt%, about 11 wt%, about 12 wt%, about 13 wt%, about 14 wt%, about 15 wt%, about 16 wt%, about 17 wt%, about 18 wt%, about 19 wt%, about 20 wt%, about 21 wt%, about 22 wt%, about 23 wt%, about 24 wt%, about 25 wt%, about 26 wt%, about 27 wt%, about 28 wt%, about 29 wt%, about 30 wt%, about 31 wt%, about 32 wt%, about 33 wt%, about 34 wt%, about 35 wt%, about 36 wt%, about 37 wt%, about 38 wt%, about 39 wt%, about 40 wt%, about 41 wt%, about 42 wt%, about 43 wt%, about 44 wt%, about 45 wt%, about 46 wt%, about 47 wt%, about 48 wt%, about 49 wt%, about 50 wt%, about 51 wt%, about 52 wt%, about 53 wt%, about 54 wt%, about 55 wt%, about 56 wt%, about 57 wt%, about 58 wt%, about 59 wt%, about 60 wt%, about 61 wt%, about 62 wt%, about 63 wt%, about 64 wt%, about 65 wt%, about 66 wt%, about 67 wt%, about 68 wt%, about 69 wt%, about 70 wt%, about Amount %, about 21% by weight, about 22% by weight, about 23% by weight, about 24% by weight, about 25% by weight, about 26% by weight, about 27% by weight, about 28% by weight, about 29% by weight, about 30% by weight, about 31% by weight, about 32% by weight, about 33% by weight , about 34% by weight, about 35% by weight, about 36% by weight, about 37% by weight, about 38% by weight, about 39% by weight, about 40% by weight, about 41% by weight, about 42% by weight, about 43% by weight, about 44% by weight, about 45% by weight, about 46% by weight, about 4 7% by weight, approximately 48% by weight, approximately 49% by weight, approximately 50% by weight, approximately 51% by weight, approximately 52% by weight, approximately 53% by weight, approximately 54% by weight, approximately 55% by weight, approximately 56% by weight, approximately 57% by weight, approximately 58% by weight, approximately 59% by weight, approximately 60% by weight Amount%, about 61% by weight, about 62% by weight, about 63% by weight, about 64% by weight, about 65% by weight, about 66% by weight, about 67% by weight, about 68% by weight, about 69% by weight, about 70% by weight, about 71% by weight, about 72% by weight, about 73% by weight, About 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% by weight.
[0233] In one embodiment, the weight percentage of PEG or mPEG in the PLA-PEG or PLA-mPEG diblock copolymer is about 1% to 99%, 2% to 95%, 3% to 90%, 4% to 75%, 5% to 50%, 10% to 45%, 15% to 40%, 18% to 35%, or 20% to 30% by weight.
[0234] In one embodiment, the weight percentage of PEG or mPEG in the PLA-PEG or PLA-mPEG diblock copolymer is about 25% by weight.
[0235] In one embodiment, the weight percentage of mPEG in the PLA-mPEG diblock copolymer is about 25% by weight.
[0236] The present disclosure provides a composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising a poly(lactide-co-glycolide) (PLGA) polymer, which can be synthesized with polyethylene glycol (PEG) or polyethylene glycol methyl ether (mPEG) to prepare diblock copolymers (PLGA-PEG and PLGA-mPEG) to allow for controlled release of dactinomycin. In one embodiment, the PLGA-mPEG copolymer has the general structure shown in the following scheme:
[0237] [ka]
[0238] The hydrophilic PEG (and mPEG) moieties are oriented toward the surface of the nanoparticles and act as a barrier to reduce interactions with external molecules through steric and hydration repulsion. These compositions can have a longer half-life in the systemic circulation compared to unmodified nanoparticles (i.e., "non-PEGylated" or "non-mPEGylated" nanoparticles).
[0239] In one embodiment, drug release from PLGA-PEG and PLGA-mPEG nanoparticles occurs by diffusion. In one embodiment, drug release from PLGA-PEG and PLGA-mPEG nanoparticles occurs by polymer degradation. In one embodiment, drug release from PLGA-PEG and PLGA-mPEG nanoparticles occurs by both diffusion and polymer degradation.
[0240] The ratio of PEG or mPEG to PLGA can affect the clearance of the nanoparticles from the systemic circulation.
[0241] In one embodiment, the weight percentage of PEG or mPEG in the PLGA-PEG or PLGA-mPEG diblock copolymer is about 1 wt%, about 2 wt%, about 3 wt%, about 4 wt%, about 5 wt%, about 6 wt%, about 7 wt%, about 8 wt%, about 9 wt%, about 10 wt%, about 11 wt%, about 12 wt%, about 13 wt%, about 14 wt%, about 15 wt%, about 16 wt%, about 17 wt%, about 18 wt%, about 19 wt%, about 20 wt%, about 21 wt%, about 22 wt%, about 23 wt%, about 24 wt%, about 25 wt%, about 26 wt%, about 27 wt%, about 28 wt%, about 29 wt%, about 30 wt%, about 31 wt%, about 32 wt%, about 33 wt%, about 34 wt%, about 35 wt%, about 36 wt%, about 37 wt%, about 38 wt%, about 39 wt%, about 40 wt%, about 41 wt%, about 42 wt%, about 43 wt%, about 44 wt%, about 45 wt%, about 46 wt%, about 47 wt%, about 48 wt%, about 49 wt%, about 50 wt%, about 51 wt%, about 52 wt%, about 53 wt%, about 54 wt%, about 55 wt%, about 56 wt%, about 57 wt%, about 58 wt%, about 59 wt%, about 60 wt%, about 61 wt%, about 62 wt%, about 63 wt%, about 64 wt%, about 65 wt%, about 66 wt%, about 67 wt%, about 68 wt%, about 69 wt%, about 70 wt%, about 0% by weight, approximately 21% by weight, approximately 22% by weight, approximately 23% by weight, approximately 24% by weight, approximately 25% by weight, approximately 26% by weight, approximately 27% by weight, approximately 28% by weight, approximately 29% by weight, approximately 30% by weight, approximately 31% by weight, approximately 32% by weight, approximately 33% by weight %, about 34% by weight, about 35% by weight, about 36% by weight, about 37% by weight, about 38% by weight, about 39% by weight, about 40% by weight, about 41% by weight, about 42% by weight, about 43% by weight, about 44% by weight, about 45% by weight, about 46% by weight, about 47% by weight, approximately 48% by weight, approximately 49% by weight, approximately 50% by weight, approximately 51% by weight, approximately 52% by weight, approximately 53% by weight, approximately 54% by weight, approximately 55% by weight, approximately 56% by weight, approximately 57% by weight, approximately 58% by weight, approximately 59% by weight, approximately 60 Weight%, about 61% by weight, about 62% by weight, about 63% by weight, about 64% by weight, about 65% by weight, about 66% by weight, about 67% by weight, about 68% by weight, about 69% by weight, about 70% by weight, about 71% by weight, about 72% by weight, about 73% by weight , about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% by weight.
[0242] In one embodiment, the weight percentage of PEG or mPEG in the PLGA-PEG or PLGA-mPEG diblock copolymer is about 1% to 99%, 2% to 95%, 3% to 90%, 4% to 75%, 5% to 50%, 10% to 47%, 15% to 45%, 20% to 42%, or 25% to 45% by weight.
[0243] In one embodiment, the weight percentage of PEG or mPEG in the PLGA-PEG or PLGA-mPEG diblock copolymer is about 35% by weight.
[0244] In one embodiment, the weight percentage of mPEG in the PLGA-mPEG diblock copolymer is about 35% by weight.
[0245] The present disclosure also provides a composition as disclosed herein comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising one or more polymers, the nanoparticles having an average size of about 100 nm, 101 nm, 102 nm, 103 nm, 104 nm, 105 nm, 106 nm, 107 nm, 108 nm, 109 nm, 110 nm, 111 nm, 112 nm, 113 nm, 114 nm, 115 nm, , 116nm, 117nm, 118nm, 119nm, 120nm, 121nm, 122nm, 123nm, 124nm, 125nm, 126nm, 127nm, 128nm, 129nm, 130 nm, 131nm, 132nm, 133nm, 134nm, 135nm, 136nm, 137nm, 138nm, 139nm, 140nm, 141nm, 142nm, 143nm, 144nm, 14 5nm, 146nm, 147nm, 148nm, 149nm, 150nm, 151nm, 152nm, 153nm, 154nm, 155nm, 156nm, 157nm, 158nm, 159nm, 160nm, 161nm, 162nm, 163nm, 164nm, 165nm, 166nm, 167nm, 168nm, 169nm, 170nm, 171nm, 172nm, 173nm, 174n m, 175 nm, 176 nm, 177 nm, 178 nm, 179 nm, 180 nm, 181 nm, 182 nm, 183 nm, 184 nm, 185 nm, 186 nm, 187 nm, 188 nm, 189 nm, 190 nm, 191 nm, 192 nm, 193 nm, 194 nm, 195 nm, 196 nm, 197 nm, 198 nm, 199 nm, or 200 nm.
[0246] Further, the disclosure provides a composition as disclosed herein comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising one or more polymers, the nanoparticles having an average size of about 100 nm to about 110 nm, about 105 nm to about 115 nm, about 110 nm to about 120 nm, about 115 nm to about 125 nm, about 120 nm to about 130 nm, about 125 nm to about 135 nm, about 130 nm to about 140 nm, about 135 nm to about 145 nm, about 135 nm to about 150 nm, about 150 nm to about 160 nm, about 160 nm to about 170 nm, about 170 nm to about 180 nm, about 180 nm to about 190 nm, about 190 nm to about 200 nm, about 200 nm to about 210 nm, about 210 nm to about 220 nm, about 220 nm to about 230 nm, about 230 nm to about 240 nm, about 240 nm to about 250 nm, about 250 nm to about 260 nm, about 260 nm to about 270 nm, about 270 nm to about 280 nm, about 280 nm to about 290 nm, about 290 nm to about 300 nm, about 300 nm to about 310 nm, about 310 nm to about 320 nm, about 320 nm to about 330 nm, about 330 nm to about 340 nm, about 340 nm to about 350 nm, about 350 nm to about 360 nm, about 350 nm to about 370 nm, about 370 nm to about 380 nm, about 380 nm to about 390 In one embodiment, the composition has a diameter of about 0 nm to about 140 nm, about 135 nm to about 145 nm, about 140 nm to about 150 nm, about 145 nm to about 155 nm, about 150 nm to about 160 nm, about 155 nm to about 165 nm, about 160 nm to about 170 nm, about 165 nm to about 175 nm, about 170 nm to about 180 nm, about 175 nm to about 185 nm, about 180 nm to about 190 nm, about 185 nm to about 195 nm, or about 190 nm to about 200 nm.
[0247] In one embodiment, nanoparticle size can be calculated using methods known in the art, for example, using a Malvern Nano-ZS Zetasizer.
[0248] The present disclosure also provides any of the compositions disclosed herein comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the composition comprising one or more polymers and further comprising a surfactant.
[0249] In one embodiment, the surfactant comprises about 0.01% to about 10.0% by weight of each nanoparticle. In one embodiment, the surfactant comprises about 0.1% to about 5.0% by weight of each nanoparticle. For example, the surfactant comprises about 0.2% to about 4.0% by weight of each nanoparticle, about 0.5% to about 3.0% by weight of each nanoparticle, or about 1.0% to about 2.5% by weight of each nanoparticle.
[0250] In one embodiment, the surfactant is about 0.001%, about 0.005%, about 0.01%, about 0.05%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, about 3.0%, about 3.1%, about 3.2%, about 3.3%, about 3.4%, about 3.5%, about 3.6%, about 3.7%, about 3.8%, about 3.9 ... %, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, about 3.0%, about 3.1%, about 3.2%, about 3.3%, about 3.4%, about 3.5%, about 3.6%, about 3.7%, about 3.8%, about 3.9%, about 4.0%, about 4.1%, about 4.2%, about 4.3%, about 4.4%, about 4.5%, about 4.6%, about 14.7%, about 4.8%, about 4.9%, or about 5.0% by weight.
[0251] In one embodiment, the surfactant comprises less than 2.0% by weight of each nanoparticle.
[0252] The disclosure also provides any of the compositions disclosed herein comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, comprising one or more polymers, and further comprising a surfactant, the surfactant being polyvinyl alcohol, Tween® 20, Tween® 80, Vitamin E TPGS, sodium cholate, bile salts (e.g., sodium taurodeoxycholate), polyethylene glycol (e.g., PEG 600, PEG, PEG 4500, Brij® (e.g., 20, 35, 58, etc.)), and / or poloxamer (e.g., poloxamer 188, poloxamer 407). In one embodiment, the surfactant is polyvinyl alcohol. In one embodiment, the surfactant is polyvinyl alcohol, the polyvinyl alcohol is 80% hydrolyzed and has a molecular weight of about 9,000 to about 10,000 Da.
[0253] The present disclosure also provides any of the compositions disclosed herein comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the compositions comprising one or more polymers and further comprising about 1% to about 50% by weight of dactinomycin.
[0254] Further, the present disclosure provides a composition as disclosed herein comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, comprising one or more polymers, and having a molecular weight of about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 102%, 104%, 106%, 108%, 109%, 110%, 111%, 120%, 122%, 130%, 131%, 132%, 133%, 134%, 1 In one embodiment, the composition further comprises 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, or 50% by weight of dactinomycin.
[0255] The present disclosure also provides any of the compositions disclosed herein comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the compositions comprising one or more polymers and further comprising about 5% to about 15% by weight of dactinomycin.
[0256] The present disclosure further provides compositions comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the compositions comprising a phospholipid that functions as a liquid surfactant capable of forming liquid crystals, and further comprising purified water, a buffer (e.g., glycine), an oil component (e.g., D,L-alpha-tocopherol), and a surfactant (e.g., sodium deoxycholate or polyvinyl alcohol). Examples of phospholipids in these compositions include, but are not limited to, phosphatidylcholine with negatively charged phospholipids (phospholipon® 80), phosphatidylcholine-rich lecithin moieties (phospholipon® 85G), and phosphatidylcholine stabilized with 0.1% ascorbyl palmitate (phospholipon® 90G). (See, e.g., U.S. Pat. No. 7,713,440; Particle Sciences Technical Brief, 2012, Vol. 4; Anderson, D. et al. CRC Concise Encyclopedia of Nanotechnology, Taylor & Francis Group, LLC, 2016, p. 5, all of which are incorporated herein by reference).
[0257] In one embodiment, the composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, which comprises phospholipids, can be prepared by any method known in the art.For example, blank phospholipid composition (e.g., 25mL of phospholipid composition comprising Phospholipon® 90G, purified water, glycine, D,L-alpha-tocopherol, sodium dicarboxylate) and dactinomycin (e.g., 375mg) are mixed by vigorous stirring for several hours (e.g., 5 hours), and then filtered using a 0.45μm CA (cellulose acetate) filter.
[0258] The present disclosure provides compositions comprising dactinomycin encapsulated in nanoparticles in association with at least one pharma- ceutically acceptable excipient or carrier.
[0259] As used herein, the terms "encapsulation," "encapsulated," and the like, mean that dactinomycin and / or other drugs or agents are enclosed (e.g., completely or partially) in, associated with, and / or adsorbed to or on the nanoparticles.
[0260] A "composition" refers to any formulation containing the dactinomycin nanoparticle composition described herein in a form suitable for administration to a subject. In one embodiment, the composition is in bulk or unit dosage form. The unit dosage form is any of a variety of forms including, for example, a capsule, an IV bag, a tablet, a single pump of an aerosol inhaler, or a vial. The amount of active ingredient (e.g., a formulation of the disclosed compound or its salt, hydrate, solvate, or isomer) in a unit dose of the composition is an effective amount and varies according to the particular treatment involved. Those skilled in the art will recognize that it may be necessary to vary the dosage routine depending on the age and condition of the patient. The dosage will also depend on the route of administration. The compositions of the present disclosure may be administered by any route, although preferred routes of administration include intravenous injection or infusion. In one embodiment, the active compound is mixed under sterile conditions with a pharma- ceutically acceptable carrier and with any preservatives, buffers, or propellants required.
[0261] As used herein, the phrase "pharmacologically acceptable" means those compounds, substances, compositions, carriers, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0262] "Pharmaceutically acceptable excipient" means an excipient that is generally safe, non-toxic, and not biologically or otherwise harmful, useful in the preparation of compositions, and includes excipients that are applicable for veterinary use as well as human pharmaceutical use. As used in the specification and claims, "pharmaceutically acceptable excipient" includes both one excipient and more than one excipient.
[0263] The present disclosure also provides compositions as disclosed herein comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles, the compositions comprising one or more polymers, and further comprising one or more other chemotherapeutic agents in addition to dactinomycin, which may be encapsulated in the nanoparticles together with dactinomycin and / or may not be encapsulated in the same nanoparticle as dactinomycin.
[0264] In one embodiment, the other chemotherapeutic agents include, but are not limited to, topoisomerase inhibitors (e.g., etoposide, irinotecan, topotecan, camptothecin, lamellarin D, teniposide, mitoxantrone, amsacrine, ellipticine, aurintricarboxylic acid, HU-331), platinum-based therapeutic agents (e.g., cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, picoplatin, satraplatin), anthracycline antibiotics (e.g., daunorubicin, doxorubicin, epirubicin, idarubicin), taxanes (e.g., paclitaxel, docetaxel, baccatin, III, 10-deacetylbaccatin), tyrosine kinase inhibitors (e.g., imatinib, enzastaurin, dasatinib, erlotinib, gefitinib, lapatinib, nilotinib, sorafenib, sunitinib, everolimus, sirolimus, temsirolimus), nucleoside analogues (e.g., cytarabine, gemcitabine, capecitabine), FLT3 inhibitors (e.g., Rydapt® (midostaurin), sorafenib, lestaurtinib, quizartinib, ponatinib, crenolanib, and gilteritinib), and hypermethylation inhibitors (e.g., azacitidine, decitabine, and zebularine).
[0265] The term "antioxidant" as used herein includes, but is not limited to, vitamin C, retinoic acid (eg, all-trans-retinoic acid), amifostine, and N-acetylcysteine.
[0266] The term "anti-inflammatory agent" as used herein includes, but is not limited to, pentoxifylline, nonsteroidal anti-inflammatory drugs (NSAIDs) (eg, ibuprofen).
[0267] The term "growth differentiation promoter" includes, but is not limited to, glutamine.
[0268] The nanoparticle-encapsulated dactinomycin composition of the present disclosure is formulated to be compatible with the intended route of administration. An example of an administration route is intravenous administration. Solutions or suspensions used for intravenous use may contain the following components: a sterile diluent such as water for injection, saline, fixed oils, polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methylparabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates, or phosphates, and agents for adjusting tonicity such as sodium chloride or dextrose. The pH may be adjusted with acids or bases such as hydrochloric acid or sodium hydroxide. Parenteral formulations may be enclosed in glass or plastic ampoules, disposable syringes, or multiple dose vials.
[0269] The nanoparticle-encapsulated dactinomycin compositions of the present disclosure may be administered to a subject in need thereof by one or more routes commonly used for chemotherapeutic treatment. For example, the nanoparticle-encapsulated dactinomycin compositions of the present disclosure may be injected or infused (e.g., administered intravenously) into the subject's bloodstream. The dose selected should be sufficient to provide effective treatment, but not so high as to cause unacceptable side effects (e.g., mucositis). The state of the patient's disease condition (e.g., cancer, precancer, etc.) and health status should preferably be closely monitored during and for an appropriate period after treatment.
[0270] The term "therapeutically effective amount" as used herein refers to an amount of dactinomycin composition encapsulated in nanoparticles that treats, ameliorates, or prevents an identified disease or condition, or that exhibits a detectable therapeutic or suppressive effect. The effect can be detected by any assay method known in the art. The exact effective amount for a subject will depend on the subject's weight, size, and health; the nature and extent of the condition; and the therapeutic agent or combination of therapeutic agents selected for administration. The therapeutically effective amount for a given situation can be calculated by routine experimentation that is within the skill and judgment of the clinician. In one embodiment, the disease or condition being treated is MDS. In one embodiment, the disease or condition being treated is cancer. In another embodiment, the disease or condition being treated is AML.
[0271] The term "drug holiday" as used herein refers to the length of time between administrations of any of the nanoparticle-encapsulated dactinomycin compositions of the present disclosure for the treatment of MDS and / or cancer. In one embodiment, the drug holiday is 1 week, 2 weeks, 3 weeks, 4 weeks, or any length of time in between. For example, the cancer being treated is AML.
[0272] For any composition of the disclosure, the therapeutically effective amount may be estimated initially in cell culture assays (e.g., tumor cell assays) or in animal models (usually rats, mice, rabbits, dogs, or pigs). Animal models may be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes of administration in humans. Therapeutic / prophylactic efficacy and toxicity may be assessed by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED 50 (the dose that is therapeutically effective in 50% of the population), and LD 50 (the dose lethal to 50% of the population). The ratio of toxic to therapeutic effects of a dose is the therapeutic index, and the LD 50 / ED 50Compositions which exhibit large therapeutic indices are preferred. The dosage can vary within this range depending on the dosage form used, sensitivity of the patient, and the route of administration.
[0273] Dosage and administration are adjusted to provide sufficient levels of the active agent or to maintain the desired effect. Factors that can be taken into account include the disease state, the subject's general health, the subject's age, weight, and sex, diet, time and frequency of administration, co-formulations, reaction sensitivities, and tolerance / response to therapy. Long-acting compositions can be administered every 3-4 days, every week, or once every two weeks, depending on the half-life and clearance rate of the particular formulation.
[0274] The nanoparticle-encapsulated dactinomycin compositions of the present disclosure can be prepared by conventional means, for example, by the methods disclosed in McCall, R Let al. J. Vis. Exp. (82), e51015.
[0275] Any of the nanoparticle encapsulated dactinomycin compositions disclosed herein can be prepared according to the following general procedure: A. Prepare a stock solution of dactinomycin (25 mg / mL) in organic solvent. B. Prepare stock solutions of polymer (e.g., 25 mg / mL for PLA polymers such as Resomer® R 202S and R 203H, or 50 mg / mL for Resomer® D5050 DLG mPEG 5000 (35% by weight, PEG) and 100 DL mPEG 5000 (25% by weight, PEG)) in organic solvent. C. The dactinomycin solution is added to the polymer solution until a polymer to API amount ratio of 10:1 (w / w) is reached. D. Vortex the final solution until homogenous. E. Prepare an aqueous surfactant solution (aqueous phase). F. Dactinomycin nanoparticle emulsions are formed by adding the polymer / dactinomycin solution to a small amount of the aqueous phase while vortexing the aqueous phase at high speed until the entire polymer solution has been added and an organic:aqueous volume ratio of approximately 1:7 is reached. G. After continued vortexing, transfer the mixture to a sonicator at about 0 °C and sonicate for several minutes until the desired nanoparticle size (e.g., about 100 nm to about 200 nm) is obtained. H. Stir the surfactant solution into the bulk aqueous phase and stir vigorously at room temperature until the organic solvent has completely evaporated.
[0276] The encapsulation efficiency of this procedure is about 1-50% (e.g., 30%). For example, if this procedure is performed with 100 mg of free dactinomycin, about 1-50 mg (e.g., about 30 mg) of dactinomycin will be encapsulated in the nanoparticles.
[0277] In one embodiment, any of the nanoparticle encapsulated dactinomycin compositions disclosed herein are purified by centrifuging the solidified or hardened nanoparticles, removing the supernatant, and washing the dactinomycin nanoparticles with ddH2O followed by an additional centrifugation for several minutes to obtain a pellet.
[0278] In one embodiment, any of the nanoparticle encapsulated dactinomycin compositions disclosed herein are purified to remove free dactinomycin by centrifuging the solidified or hardened nanoparticles, removing the supernatant, and washing the dactinomycin nanoparticles with ddH2O, followed by an additional centrifugation for several minutes to obtain a pellet.
[0279] In one embodiment, any of the nanoparticle-encapsulated dactinomycin compositions disclosed herein can be purified to remove 95%, 96%, 97%, 98%, 99% or more of the free (unencapsulated) dactinomycin remaining in the composition. Thus, in any of the compositions or formulations described herein, the amount of free dactinomycin is less than about 5% by weight (i.e., less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%) of the amount of dactinomycin encapsulated in the nanoparticles. In one embodiment, larger nanoparticles are removed from any of the nanoparticle-encapsulated dactinomycin compositions disclosed herein by resuspending the pellet in ddH2O and centrifuging for several minutes, after which the supernatant is collected, concentrated using a centrifugal filter, and centrifuged at 14,000 x rpm for an additional few minutes to remove the free dactinomycin.
[0280] In one embodiment, the nanoparticle encapsulated dactinomycin composition prepared by this method can be used directly.
[0281] In one embodiment, any of the nanoparticle encapsulated dactinomycin compositions disclosed herein can be stored at 4° C. for up to several weeks.
[0282] In one embodiment, the nanoparticle encapsulated dactinomycin compositions disclosed herein can be lyophilized and cryoprotected with sucrose (10-30%) prior to storage and lyophilized prior to use. Any other suitable cryopreservative known in the art may be used.
[0283] The drug loading of the nanoparticle encapsulated dactinomycin compositions disclosed herein was evaluated using HPLC.
[0284] Further guidance on the preparation of ActD nanoparticle formulations is provided in the Examples section and in McCall, R Let al. J. Vis. Exp. (82), e51015, which is incorporated by reference in its entirety.
[0285] The nanoparticle-encapsulated dactinomycin composition of the present disclosure can be manufactured on a larger scale. To simplify the process, the nanoparticles can be made using a high-pressure homogenizer instead of an ultrasonicator. In addition, tangential flow filtration / diafiltration can be used instead of centrifugation to remove free dactinomycin and concentrate the nanoparticles. Also, lyophilization protection excipients (e.g., sucrose, trehalose, and mannitol) can be added to the nanoparticles during storage, which can then be lyophilized before use.
[0286] Compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Suitable carriers for intravenous administration include physiological saline, bacteriostatic water for injection, Cremophor EL TM(BASF, Passipany, NJ), or phosphate buffered saline (PBS). In all cases, the composition should be sterile and fluid to the extent that easy syringeability exists. The composition must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be, for example, a solvent or dispersion medium containing water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants. The action of microorganisms can be prevented by various antibacterial and antifungal agents, such as, for example, parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal. In many cases, it is preferable to include isotonic agents, for example, sugars, polyalcohols (for example, mannitol, sorbitol), and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
[0287] Sterile injectable solutions can be prepared by mixing the required amount of the dactinomycin nanoparticle composition in a suitable solvent with one or a combination of the ingredients listed above, and optionally filtering to sterilize. Dispersions are typically prepared by mixing the active dactinomycin compound in a sterile vehicle that contains a basic dispersion medium and the required other ingredients listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation methods are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus any additional desired ingredient from its previously sterile-filtered solution.
[0288] The active compounds (e.g., dactinomycin and nanoparticle-encapsulated dactinomycin) can be prepared with pharma- ceutically acceptable carriers that protect the compound from rapid elimination from the body (e.g., controlled release formulations, including implants and microencapsulated delivery systems). Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparing such formulations will be apparent to those skilled in the art. Raw materials can also be obtained commercially, primarily from Alza Corporation, Evonik, and Nova Pharmaceuticals.
[0289] Formulation of oral or parenteral compositions in dosage unit form is particularly advantageous for ease of administration and uniformity of administration.As used herein, dosage unit form refers to a physically discrete unit suitable as a unitary dosage for a subject to be treated, each unit containing a predetermined amount of active compound calculated to produce a desired therapeutic effect, including necessary pharmaceutical carriers.The specification of dosage unit form of the present disclosure is determined and directly depends on the inherent characteristics of active compound and the specific therapeutic effect to be achieved.
[0290] In therapeutic applications, the dosage of dactinomycin nanoparticle compositions used in accordance with the present disclosure will vary depending on the age, weight, and clinical condition of the recipient patient, as well as the experience and judgment of the clinician or practitioner administering the therapy, among other factors that will affect the selected dosage. In general, the dosage should be sufficient to slow, and preferably cause regression of, tumor growth, and preferably complete regression of MDS and / or cancer. Dosages can range from about 1 μg / kg per day to about 30 μg / kg per day (this dosage is dependent on the patient's weight (kg), body surface area (m2), and the like), in a single dose, divided doses, or sustained dose. 2), may be adjusted according to age (years). An effective amount of a pharmaceutical agent is an amount that produces an objectively discernible improvement as seen by a clinician or other expert observer. For example, tumor regression in a patient can be measured based on tumor diameter. A decrease in tumor diameter indicates regression. Regression is also indicated by failure of tumor to recur after treatment is completed. As used herein, the term "effective dosage" refers to an amount of an active compound that produces a desired biological effect in a subject or cell.
[0291] The compositions can be included in a container, pack, or dispenser together with instructions for administration.
[0292] Dactinomycin can form salts, and all of these salt forms are considered within the scope of this disclosure.
[0293] As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds where the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like. Pharmaceutically acceptable salts include the conventional non-toxic salts or quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such common non-toxic salts include, but are not limited to, 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, glycolylarsanilic acid, hexylresorcylic acid, hydrabamic acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxymaleic acid, hydroxynaphthoic acid, isethionic acid, lactic acid, lactobioic acid, and the like. and salts obtained from inorganic and organic acids selected from the group consisting of carboxylic acid, laurylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, napsylic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, subacetic acid, succinic acid, sulfamic acid, sulfanilic acid, sulfuric acid, tannic acid, tartaric acid, toluenesulfonic acid, and commonly occurring amino acids (e.g., glycine, alanine, phenylalanine, arginine, etc.).
[0294] Other examples of pharma- ceutically acceptable salts include hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, and muconic acid. The present disclosure also encompasses salts formed when an acidic proton in the parent compound is replaced with a metal ion (e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion) or coordinated with an organic base (e.g., ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, meglumine, and the like).
[0295] It should be understood that all references to pharma- ceutically acceptable salts include the solvent addition forms (solvates) or crystal forms (polymorphs), as defined herein, of the same salt.
[0296] Dactinomycin may be prepared as an ester, e.g., as a pharma- ceutically acceptable ester. For example, a carboxylic acid functional group of a compound can be converted to its corresponding ester (e.g., a methyl ester, an ethyl ester, or other ester). Additionally, an alcohol group of a compound can be converted to its corresponding ester (e.g., an acetate ester, a propionate ester, or other ester).
[0297] Dactinomycin may be prepared as a prodrug, e.g., as a pharma- ceutically acceptable prodrug. The terms "pro-drug" and "prodrug" are used interchangeably herein to refer to any compound that releases an active parent drug in vivo. Prodrugs enhance various desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, productivity, etc.). Thus, the compounds of the present disclosure may be delivered in the form of a prodrug. Thus, the present disclosure is intended to cover prodrugs of the presently claimed compounds, methods of delivering same, and compositions containing same. "Prodrug" is intended to include any covalently bonded carrier that releases an active parent drug of the present disclosure in vivo when such prodrug is administered to a subject. Prodrugs of the present disclosure are prepared by modifying functional groups contained in the compound, which modifications are cleaved, either by routine manipulation or in vivo, to yield the parent compound. Prodrugs include compounds of the disclosure in which a hydroxy, amino, sulfhydryl, carboxy, or carbonyl group is bonded to any group that can be cleaved in vivo to form a free hydroxyl, free amino, free sulfhydryl, free carboxy, or free carbonyl group, respectively.
[0298] Examples of prodrugs include, but are not limited to, esters (e.g., acetate, dialkylaminoacetates, formates, phosphates, sulfates, and benzoates) and carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups, esters (e.g., ethyl esters, morpholinoethanol esters) of carboxyl functional groups, N-acyl derivatives (e.g., N-acetyl), N-Mannich bases, Schiff bases, and enaminones of amino functional groups, and oximes, acetals, ketals, enol esters, and the like of ketone and aldehyde functional groups in the compounds of the present disclosure. See Bundegaard, H., Design of Prodrugs, p1-92, Elsevier, New York-Oxford (1985).
[0299] The compositions of the present disclosure may be administered orally, nasally, transdermally, pulmonary, inhalation, buccal, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally, and parenterally. In one embodiment, the compounds are administered orally. Those skilled in the art will recognize the advantages of certain routes of administration.
[0300] Compositions of the present disclosure formulated for oral administration include materials granulated using traditional pharmaceutical methods or compositions adsorbed onto pharma- ceutically acceptable excipients (e.g., microcrystalline cellulose, mannitol, sorbitol, starch, ion exchange resins, etc.) and compressed into tablets or filled into capsules. The tablets or capsules may optionally be enteric coated for delivery to the small intestine or colon.
[0301] The nanoparticulate formulations of dactinomycin disclosed in the present application can improve the oral bioavailability of dactinomycin by a particle uptake pathway across the intestinal mucosa.
[0302] Additionally, the nanoparticle compositions of the present application can be incorporated into a controlled release tablet or matrix to further tailor the release of dactinomycin while maintaining efficacy.
[0303] Alternatively, the nanoparticle compositions of the present application may be formulated as pellets or beads, produced using extrusion-spheronization or drug-layered onto a non-pareil using fluidized bed Wurster coating. The beads may be coated with release-controlling or enteric polymers to further modify drug release.
[0304] Dactinomycin beads can also be combined with beads of other chemotherapy drugs in predetermined ratios and loaded into capsules for effective administration.
[0305] The compound, or a pharma- ceutically acceptable salt, ester, or prodrug thereof, may be administered orally, nasally, transdermally, pulmonary, inhalation, buccal, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally, and parenterally. In one embodiment, the compound is administered orally. Those skilled in the art will recognize the advantages of certain administration routes.
[0306] Systemic administration can be achieved by transmucosal or transdermal means. For transmucosal or transdermal administration, a penetrant appropriate to the barrier to be permeated is used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be achieved by using nasal sprays or suppositories. For transdermal administration, the active compound is formulated into ointments, salves, gels, or creams, as is generally known in the art.
[0307] Sterile injectable solutions can be prepared by mixing the required amount of active compound in a suitable solvent with one or a combination of the above listed ingredients, and optionally sterilizing by filtration. Dispersions are usually prepared by mixing the active compound with a sterile medium that contains a basic dispersion medium and other required ingredients other than those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation method is vacuum drying and freeze-drying, which produces a powder of the active ingredient plus any additional desired ingredient from the solution previously sterile-filtered.
[0308] Oral compositions generally contain inert diluents or edible pharma- ceutically acceptable carriers. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of therapeutic oral administration, active compounds can be mixed with excipients and used in the form of tablets, lozenges, or capsules. Oral compositions can also be prepared with fluid carriers for use as mouthwash, in which case the compound in the fluid carrier is applied orally, rinsed and expectorated, or swallowed. Pharmaceutically acceptable binding agents and / or auxiliary substances can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
[0309] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
[0310] Dosage regimens using the present compounds are selected according to a variety of factors, including the type, species, age, weight, sex, and medical condition of the patient, the severity of the condition being treated, the route of administration, the renal and hepatic function of the patient, the particular compound or salt thereof being used, etc. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
[0311] The dosing regimen can be daily administration of the disclosed compound (e.g., every 24 hours). The dosing regimen can be daily administration, for example, for at least 2 consecutive days, at least 3 consecutive days, at least 4 consecutive days, at least 5 consecutive days, at least 6 consecutive days, at least 7 consecutive days. Administration can be more than once a day, for example, 2, 3, or 4 times a day (per 24 hours). The dosing regimen can be daily administration followed by at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days of non-administration. For example, the disclosed compound is administered at least once a 24-hour period, followed by at least 6 days of non-administration, and then administered to a subject in need thereof.
[0312] Techniques for formulation and administration of the disclosed compounds of this disclosure are described in Remington: The Science and Practice of Pharmacy, 1999. th edition, Mack Publishing Co., Easton, PA (1995). In some embodiments, the compounds described herein and their pharma- ceutically acceptable salts are used in pharmaceutical preparations in combination with a pharma- ceutically acceptable carrier or diluent. Suitable pharma- ceutically acceptable carriers include inert solid fillers or diluents, and sterile aqueous or organic solutions. The compounds will be included in such compositions in an amount sufficient to provide the desired dosage within the range described herein. Combination therapy
[0313] The dactinomycin compositions of the present disclosure may be administered in combination with one or more other chemotherapeutic agents, such as a topoisomerase inhibitor, a platinum-based therapeutic agent, an anthracycline antibiotic, a taxane, a tyrosine kinase inhibitor, a nucleoside analogue, an FLT3 inhibitor, or a hypermethylation inhibitor.
[0314] In one embodiment, the dactinomycin nanoparticles and other chemotherapeutic agents may be administered simultaneously.
[0315] In one embodiment, dactinomycin and another chemotherapeutic agent can be administered simultaneously, with both encapsulated in the same nanoparticle.
[0316] In one embodiment, dactinomycin and other chemotherapeutic agents may be administered simultaneously or sequentially, but encapsulated in different nanoparticles.
[0317] In one embodiment, dactinomycin and another chemotherapeutic agent can be administered simultaneously or sequentially, with dactinomycin being encapsulated in nanoparticles and the other chemotherapeutic agent not being encapsulated in nanoparticles.
[0318] In one embodiment, the dactinomycin nanoparticles and the other chemotherapeutic agent can be administered separately, i.e., sequentially. For example, the dactinomycin nanoparticles can be administered before the other chemotherapeutic agent. Alternatively, the dactinomycin nanoparticles can be administered after the other chemotherapeutic agent.
[0319] In one embodiment, the interval between administration of the dactinomycin nanoparticles and the other chemotherapeutic agent can be minutes, hours, or days. For example, the interval between administration of the dactinomycin nanoparticles and the other chemotherapeutic agent can be 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 1 day, 1.5 days, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, or 30 days. In one embodiment, the interval between administration of the dactinomycin nanoparticles and the other chemotherapeutic agent is greater than one month.
[0320] Examples of topoisomerase inhibitors include, but are not limited to, irinotecan, topotecan, camptothecin, lamellarin D, etoposide, teniposide, mitoxantrone, amsacrine, ellipticine, aurintricarboxylic acid, and HU-331.
[0321] Examples of platinum-based therapeutic agents include, but are not limited to, cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, picoplatin, and satraplatin.
[0322] Examples of anthracycline antibiotics include, but are not limited to, daunorubicin, doxorubicin, epirubicin, or idarubicin.
[0323] Examples of taxanes include, but are not limited to, paclitaxel, docetaxel, baccatin III, and 10-deacetylbaccatin.
[0324] Examples of tyrosine kinase inhibitors include, but are not limited to, imatinib, enzastaurin, dasatinib, erlotinib, gefitinib, lapatinib, nilotinib, sorafenib, sunitinib, everolimus, sirolimus, and temsirolimus.
[0325] Examples of nucleoside analogs include, but are not limited to, cytarabine, gemcitabine, capecitabine, didanosine, vidarabine, BCX4430, emtricitabine, lamivudine, zalcitabine, abacavir, acyclovir, entecavir, stavudine, telbivudine, zidovudine, idoxuridine, and trifluridine.
[0326] Examples of FLT3 inhibitors include, but are not limited to, Rydapt® (midostaurin), sorafenib, lestaurtinib, quizartinib, ponatinib, crenolanib, and gilteritinib. (Fathi, AT et al. Eur. J. Haematol. 2017, 98:330-336).
[0327] Examples of hypermethylation inhibitors include, but are not limited to, azacytidine, decitabine, and zebularine. (Flotho, C. et al. Leukemia (2009) 23, 1019-1028 and Figueroa, ME et al. Blood (2009) 114(16), 3448-3458).
[0328] The dactinomycin compositions of the present disclosure may be administered with an FLT3 inhibitor. Clinical trials have shown efficacy of dactinomycin in approximately 60% of treated patients. Subset analysis has shown that non-responders to dactinomycin are positive for FLT3 mutations, which are seen in approximately 30% of AML patients tested. There are two types of FLT3 mutations: internal tandem duplications (ITDs) near the juxtamembrane domain of the receptor and point mutations in the activation loop of the tyrosine kinase domain (TKD mutations). TKD mutations account for approximately 7% of patients, while ITD mutations are less common in pediatric and AML patients previously classified as having MDS. (Fathi, AT et al. Eur. J. Haematol. 2017, 98:330-336).
[0329] Combining the dactinomycin compositions of the present disclosure with FLT3 inhibitors (e.g., Rydapt® (midostaurin), sorafenib, lestaurtinib, quizartinib, ponatinib, crenolanib, and gilteritinib) may provide even greater efficacy in treating patients with AML.
[0330] The dactinomycin compositions of the present disclosure may be administered with hypermethylation inhibitors. Examples of hypermethylation inhibitors include, but are not limited to, azacytidine, decitabine, and zebularine. (Flotho, C. et al. Leukemia (2009) 23, 1019-1028 and Figueroa, ME et al. Blood (2009) 114(16), 3448-3458).
[0331] For any of the methods involving administration of one or more other chemotherapeutic agents (e.g., topoisomerase inhibitors, platinum-based therapeutic agents, anthracycline antibiotics, taxanes, tyrosine kinase inhibitors, nucleoside analogs, FLT3 inhibitors, and hypermethylation inhibitors) in addition to dactinomycin, i.e., dactinomycin encapsulated in nanoparticles, it is within the ordinary level of skill of one of ordinary skill in the art to determine the appropriate therapeutically effective amount of the other chemotherapeutic agent. Any commonly used therapeutically effective amount of these additional chemotherapeutic agents may be used.
[0332] The methods of the present disclosure may be combined with the further administration of additional agents, such as, but not limited to, retinoic acid (e.g., all-trans-retinoic acid), valproic acid, histone deacetylase inhibitors, proteasome inhibitors, farnesyltransferase inhibitors, p53 stabilizers, any combination thereof, and the like.
[0333] In one aspect, the dactinomycin nanoparticles and the additional agent can be administered separately, i.e., sequentially. For example, the dactinomycin nanoparticles can be administered before the additional agent. Alternatively, the dactinomycin nanoparticles can be administered after the additional agent.
[0334] In one embodiment, the interval between administration of the dactinomycin nanoparticles and the additional agent can be minutes, hours, or days. For example, the interval between administration of the dactinomycin nanoparticles and the other chemotherapeutic agent can be 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 1 day, 1.5 days, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, or 30 days. In one embodiment, the interval between administration of the dactinomycin nanoparticles and the additional agent is greater than one month.
[0335] Histone deacetylase inhibitors include, but are not limited to, class I inhibitors (HDAC-1, HDAC-2, HDAC-3, and HDAC-8), class II inhibitors (HDAC-4, HDAC-5, HDAC-6, HDAC-7, HDAC-9, and HDAC-10), class II inhibitors (sirtuins), and class IV inhibitors (HDAC-11). For example, the histone deacetylase inhibitor is vorinostat, romidepsin, chidamide, panobinostat, belinostat, valproic acid derivatives (e.g., magnesium valproate), mocetinostat, abexinostat, entinostat, SB939, resminostat, gibinostat, xynostat, HBI-8000, quevetrin, CUDC-101, AR-42, CHR-2845, CHR-3996, 4SC-202, CG200745, ACY-1215, ME-344, or sulforaphane.
[0336] Proteasome inhibitors include, but are not limited to, lactacystin, disulfiram, epigallocatechin-3-gallate, marizomib (salinosporamide A), oprozomib, delanzomib, epoxomicin, MG132, beta-hydroxybeta-methylbutyrate, bortezomib, carfilzomib, and ixazomib.
[0337] Farnesyltransferase inhibitors include, but are not limited to, tipifarnib, lonafarnib, chaetomellic acid A, clavaric acid, FPT inhibitor I (sc-221625), FPT inhibitor II (sc-221626), FPT inhibitor III (sc-221627), FPTase inhibitor I (sc-221632), FPTase inhibitor II (sc-221633), FTI-277 trifluoroacetate, CGTI-297, L-744,832 dihydrochloride, manumicin A, gingerol, gliotoxin, and alpha-hydroxyl farnesylphosphonic acid.
[0338] p53 stabilizers include, but are not limited to, Tenovin-1, BI2536, CP-31398, RbBP6 isoform 3, CBS9106 (Chen, L et al. Cell Cycle 2016, 15(6):840-849; Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 27, No 15S, 2009:8601; Dlamini, Z. et al. Proceedings: AACR 101st Annual Meeting 2010 Apr 17-21, 2010).
[0339] The term "about" as used herein in other contexts refers to ±10%, ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, or ±1% of the recited value (e.g., amount, molecular weight, dosage, temperature, time, percentage, etc.), unless otherwise specified.
[0340] All percentages and ratios used herein are by weight unless otherwise specified. Other features and advantages of the present disclosure will become apparent from the various examples. The examples provided illustrate various components and methods useful in implementing the present disclosure. The examples do not limit the claimed invention. Based on the present disclosure, one skilled in the art will be able to identify and use other components and methods useful in implementing the present disclosure. EXAMPLES
[0341] In order that the disclosure set forth herein may be more efficiently understood, examples are provided below which are merely for illustrative purposes and should not be construed as limiting the disclosure in any way. Example 1: Pharmacokinetics of Dactinomycin
[0342] 1A and 1B are graphs showing the systemic concentration of dactinomycin over time. The data in these graphs are for 1 mg / m 2The data were obtained from 21 patients aged 16-53 years who received a 27 μg / kg dose of dactinomycin. These data indicate that the majority of dactinomycin is released in high concentrations during the first hour after administration to subjects. High initial release may contribute to toxicity and adverse events associated with dactinomycin administration.
[0343] Figure 2 shows the C max (ng / mL) (Graph A) and AUC 0-6時間 (mg / L min) (Graph B) and dactinomycin dose (mg / m 2 ) as a function of IV administration to subjects younger than 30 years of age. 2 (27 μg / kg), and the IV dose for subjects aged 30 years or older is 1.5 mg / m 2 (40μg / kg). AUC 0-6時間 Subjects with a higher AUC were more likely to experience adverse events. 0-6時間 (4 mg / L·min) was 1.46-fold greater than that in subjects not showing adverse events (2.67 mg / L·min). Example 2: Preparation of actinomycin D loaded nanoparticles
[0344] Actinomycin D was dissolved in dichloromethane (DCM) to a stock solution of 25 mg / mL ("API solution"). Resomer R 202S and R 203H were prepared in DCM at the same concentration, and Resomer D5050 DLG mPEG 5000 (35 wt%, PEG) and 100 DL mPEG 5000 (25 wt%, PEG) were prepared in DCM at 50 mg / mL. The API solution was added to the polymer solution until a polymer to API amount ratio of 10:1 (w / w) was reached. The final solution was vortexed until homogeneous before use. 2% poly(vinyl alcohol) (PVA) (molecular weight 9,000-10,000 Da, 80% hydrolyzed) was prepared as the aqueous phase with a surfactant. To make the nanoparticle emulsion, the polymer / actinomycin D solution was added dropwise to a small amount of aqueous phase while the aqueous phase was vortexed at high speed. After the entire polymer solution was added (approximately 1:7 organic:aqueous volume ratio), the formed emulsion was thoroughly vortexed for an additional 20 seconds. The mixture was immediately transferred to a sonicator (Fisher Scientific Sonic Dismembrator Model 500). The emulsion was immersed in an ice-water bath (0°C) and sonicated (65% amplitude, 20 seconds on, 8 seconds off) for 5-8 minutes until the desired particle size (<200 nm) was obtained. Nanoparticle size was periodically checked using a Malvern Nano-ZS Zetasizer. The emulsion was subsequently poured into a stirred bulk aqueous phase (2% PVA) solution and stirred (500 rpm) at room temperature for at least 3 hours until the DCM was completely evaporated.
[0345] For nanoparticle purification, the solidified or hardened nanoparticles were centrifuged at 14,000×rpm for 30 min using a fixed angle rotor (Eppendorf Centrifuge 5415C). The supernatant was discarded and the nanoparticles were washed with ddH2O and centrifuged at 14,000×rpm for another 30 min. To remove larger particles, the pellet was resuspended in ddH2O and centrifuged at 3,500×rpm for 5 min. The collected supernatant was subsequently concentrated with an Amicon® Ultra Centrifugal filter (50 kD cutoff) and centrifuged at 14,000×rpm for 10 min to remove free drug. The purified nanoparticles can be stored at 4°C for up to several weeks or lyophilized and cryoprotected in sucrose (10-30%) before being lyophilized and used fresh. Drug loading was assessed using HPLC.
[0346] Further guidance regarding the preparation of ActD nanoparticle formulations can be found in McCall, R Let al. J. Vis. Exp. (82), e51015, which is incorporated by reference in its entirety. Example 3: Representative ActD nanoparticle formulations
[0347] The following ActD nanoparticle formulations were prepared according to the above examples.
[0348] [Table 1]
[0349] For example, dactinomycin-loaded nanoparticles with Resomer® R 203 H had a calculated purity of 96.3% with an average nanoparticle size of 176.9 nm (Figure 15). Zeta cell: -23.63±0.49.
[0350] [Table 2]
[0351] For example, dactinomycin-loaded nanoparticles with Resomer® 100 DL mPEG 5000 (25% mPEG) had a calculated purity of 96.7% with an average nanoparticle size of 143.5 nm (Figure 16). Zeta cell: -45.93±2.54.
[0352] [Table 3]
[0353] The two above mentioned examples of dactinomycin loaded nanoparticles (Resomer® R 203 H (Figure 17) and Resomer® 100 DL mPEG 5000 (25% mPEG) (Figure 18)) were passed through a 200 nm surfactant free cellulose acetate membrane filter. Recovery: 79.3% (Resomer® R 203 H); 55.2% (Resomer® 100 DL mPEG 5000 (25% mPEG)). Example 4: Stability of ActD nanoparticle formulations
[0354] All four of the above dactinomycin-loaded nanoparticles were found to be stable in purified water at -20°C, 4°C, and 25°C for one month.
[0355] For example, dactinomycin-loaded nanoparticles with Resomer® R 202 S maintained greater than 94% purity for 1 month under all these conditions: Zeta cell: -11.90 ± 2.18 mV (-20°C 1 month), -5.77 ± 0.98 mV (4°C 1 month), -14.37 ± 0.47 mV (25°C / 60 RH 1 month). Storage conditions: 30% sucrose (-20°C), purified water (4°C and 25°C / 60 RH). (Figure 19)
[0356] [Table 4]
[0357] For example, dactinomycin-loaded nanoparticles with Resomer® R 203 H maintained greater than 95% purity for 1 month under all these conditions. Zeta cell: -23.63±0.49mV (T0), -0.59±3.07mV (-20°C 1 month), -9.06±1.37mV (4°C 1 month), -13.76±0.51mV (25°C / 60RH 1 month). Storage conditions: 30% sucrose (-20°C), purified water (4°C and 25°C / 60RH). (20°C: Figure 20, 4°C and 25°C / 60RH: Figure 21)
[0358] [Table 5]
[0359] For example, dactinomycin-loaded nanoparticles with Resomer® 100DL mPEG 5000 (25%) maintained greater than 95% purity for 1 month under all these conditions: Zeta cell: -45.93 ± 2.54 mV (T0), -8.74 ± 0.56 mV (1 month at -20°C), -11.07 ± 0.23 mV (1 month at 4°C), -9.89 ± 0.71 mV (1 month at 25°C / 60 RH). Storage conditions: 30% sucrose (-20°C), purified water (4°C and 25°C / 60 RH). (-20°C: Figure 22, 4°C and 25°C / 60 RH: Figure 23).
[0360] [Table 6]
[0361] For example, dactinomycin-loaded nanoparticles with Resomer® 5050DLG mPEG 5000 (35%) maintained greater than 94% purity for 1 month under all these conditions: Zeta cell: -45.93 ± 2.54 mV (T0), -3.83 ± 0.61 mV (-20°C 1 month), -9.74 ± 0.95 mV (4°C 1 month), -17.63 ± 1.06 mV (25°C / 60 RH 1 month). Storage conditions: 30% sucrose (-20°C), purified water (4°C and 25°C / 60 RH).
[0362] (-20°C: Figure 24, 4°C and 25°C / 60RH: Figure 25).
[0363] [Table 7]
[0364] For example, dactinomycin-loaded nanoparticles containing PEGylated poly-D,L-lactide retained greater than 95% purity for 1 month under all these conditions: Zeta cell: -11.07 ± 0.23 mV (1 month at 4°C), -9.89 ± 0.71 mV (1 month at 25°C / 60 RH) (Figure 26).
[0365] [Table 8]
[0366] Example 5: In Vitro Release of Dactinomycin-Loaded Nanoparticles - Comparison of mPEGylated and Non-mPEGylated Nanoparticles
[0367] Four prototype dactinomycin-loaded nanoparticle compositions demonstrated sustained release in vitro for 3-10 days.
[0368] The non-PEGylated polymer (R203H) demonstrated slower sustained release of dactinomycin over a 12 day period compared to the mPEGylated (100 DL-PEG and 50:50 DLG PEG) polymers.
[0369] Under in vivo conditions, the API released from the non-mPEGylated polymer was cleared at a faster rate than the mPEGylated polymer (Figure 27).
[0370] In a separate experiment, the in vitro release of dactinomycin-loaded nanoparticles in mPEGylated and non-mPEGylated nanoparticles was evaluated after 2 months of storage at 4° C. (FIG. 28).
[0371] We observed a slow, sustained release of dactinomycin from PEGylated poly-D,L-lactide nanoparticles (A) after 2 months of storage at 4° C. Dactinomycin release from PEGylated DLG nanoparticles (B) was similar to that observed with the unformulated API, suggesting that the nanoparticles are not stable after 2 months at 4° C. Example 6: Tolerance in rats of free actinomycin D and actinomycin D encapsulated in mPEGylated and non-mPEGylated nanoparticles
[0372] Free and formulated actinomycin D (0.5 mg / kg) were administered IV.
[0373] A significant loss in body weight was observed in rats treated with free API, which gradually recovered over 7 days after treatment.
[0374] Relatively less weight loss was noted in animals receiving dactinomycin encapsulated in PEGylated poly-D,L-lactide (DL-PEG 25%) and non-PEGylated poly-D,L-lactide (R203H).
[0375] A significant increase in body weight was observed in DL-PEG (25%)-treated rats on the 4th day compared to free actinomycin, which returned to normal levels on the 7th day.
[0376] Furthermore, rats administered R203H showed increased body weight on the 7th day.
[0377] Pharmacokinetic assessment of the concentration of available dactinomycin in the systemic circulation: C of whole plasma samples extracted into a mixture of methanol and formic acid to calculate the total amount of dactinomycin (free and encapsulated) corresponding to the PEGylated polymer MAX was significantly higher than that observed for the unformulated or unPEGylated polymer. Sufficient levels of dactinomycin encapsulated in the PEGylated polymer were still circulating after the 6 hour extraction, in contrast to the unPEGylated polymer or unformulated API.
[0378] In another experiment, rats were administered a single dose (0.5 mg / kg) of free Act D and formulated Act D via IV (intravenous) injection.
[0379] A significant loss in body weight was observed in rats following administration of free dactinomycin, which gradually recovered over 7 days after treatment (Figure 29).
[0380] Rats administered PEGylated poly-D,L-lactide nanoparticles (DL-PEG 25%) and non-PEGylated poly-D,L-lactide nanoparticles (R203H) showed relatively little weight loss (Figure 29).
[0381] A significant increase in body weight was observed in rats treated with DL-PEG (25%) on day 4 compared to free dactinomycin, which returned to normal levels on day 7 (Figure 29).
[0382] C of Act D encapsulated in PEGylated polymer MAX is significantly higher than the unformulated and free API. (Figure 30)
[0383] C for non-formulated API MAX Although the observed values are lower, this is associated with adverse effects on body weight.
[0384] Six hours after administration, sufficient Act D encapsulated in the PEGylated polymer was retained in the plasma compared to Act D encapsulated in the non-PEGylated polymer (Figure 30).
[0385] DL-PEG 25% nanoparticles demonstrate high systemic API levels with minimal adverse effects. Example 7: Pharmacokinetics of free actinomycin D and actinomycin D encapsulated in mPEGylated and non-mPEGylated nanoparticles in rats
[0386] Rats were administered a single dose (0.3 mg / kg) of unformulated and formulated actinomycin D by IV injection (Figure 31).
[0387] Plasma samples processed at the indicated times were extracted into a mixture of methanol and formic acid for calculation of the total amount of API (free and encapsulated) in the systemic circulation.
[0388] The PEGylated polymer formulated API (DL-PEG 25% and DLG-PEG 35%) remained in the systemic circulation for up to 48 hours compared to that observed with the non-PEGylated polymers (R202S and R203H).
[0389] The PK profile is similar to that observed in the rat tolerability study (see previous example).
[0390] Of the four formulated prototypes, DL-PEG (25%) exhibits the best PK profile with minimal adverse effects.
[0391] From these experiments, the human equivalent doses (HED) and Cmax values of free actinomycin D and the nanoparticle formulation were calculated as shown below: [Table 9] Example 8: Single-dose intravenous administration of free or nanoparticle-encapsulated actinomycin D in rats
[0392] Tolerability of free actinomycin D (i.e., not nanoparticle encapsulated) versus four compositions containing nanoparticle actinomycin D (NP-ActD) formulations when administered intravenously in rats.
[0393] Female Sprague-Dawley rats (HSd:SD), 6-8 weeks old and weighing 150-175 g at the time of dosing, were used in these studies. This was a single-dose study with observation for 14 days after dosing. On day 1 of the study, each animal received 900 μg / kg of free actinomycin D or NP-ActD formulation (900 μg / kg of active substance) in a fixed volume of 1 mL / kg according to the study design in the table below.
[0394] [Table 10]
[0395] Daily clinical observations, mortality, body weight, and food consumption parameters will be monitored. A complete necropsy will be performed 14 days after dosing, during which organ weights and gross findings will be examined. Organs will be preserved for future histological examination, and lungs, liver, pancreas, spleen, brain, and kidneys will be frozen in liquid nitrogen to measure actinomycin D / NP-ActD accumulation.
[0396] Blood was collected at 0.083, 0.25, 0.5, 1, 2, 6, and 24 hours post-dose for pharmacokinetic evaluation after dosing on Day 1. Serum samples are collected for clinical chemistry and whole blood samples are collected for hematology.
[0397] Body weight analysis (Figure 32). After intravenous administration of Act D and NP-ActD (900 μg / kg), animals administered free Act D consistently lost weight and failed to recover even 7 days after administration. In contrast, animals administered the four NP-ActD formulations did not show drug-related weight loss. Thus, a clear difference in the extent of weight loss was observed between animals administered free ActD and animals administered NP-ActD.
[0398] Animals in the free Act D group showed toxicity such as piloerection, decreased activity, bleeding from the nostrils, and hunched posture 3 days after administration, which worsened over time.
[0399] On the other hand, animals treated with the nanoparticle-Act D formulation appeared normal without any signs of toxicity, however, 7 days after treatment, 2-3 animals in each group treated with the NP-ActD R202S and NP-ActD DLG-PEG 35% formulations showed crusting at the injection site and slight loss of activity, which was neither severe nor progressive.
[0400] Mortality (Figure 33). On day 6 post-dosing, one animal in the free Act D group became moribund and was euthanized (per IACUC regulations to alleviate pain and distress). On day 7 post-dosing, two more animals in the free Act D group had to be euthanized due to extremely poor health.
[0401] On day 9, two additional animals in the free ActD group were euthanized due to poor health and ill health.
[0402] Thus, 13 days after administration of the free ActD group, only one sixth of the animals remained and continued to show signs of toxicity such as piloerection and discolored urine.
[0403] Thirteen days after treatment with ActD, only one animal remained and still showed poor health (ongoing study). Thus, the mortality rate in the ActD group is about 80%. In contrast, all animals in the NP-ActD formulation group survived (100% survival rate) with a tendency to show minimal toxicity such as inflammation and piloerection at the injection site, which is believed to be due to the slow release of free ActD from the nanoparticles. There was also no effect on body weight gain. As free actinomycin D is toxic in vivo, these results indicate that nanoparticle ActD formulations are effective as a method to reduce host toxicity.
[0404] The present application may be embodied in other specific forms without departing from its spirit or essential characteristics. The foregoing embodiments are therefore to be considered in all respects as illustrative, without being limited to the applications described herein. The scope of the present application is therefore indicated by the appended claims, rather than the foregoing description, and all changes that come within the meaning and range of equivalents of the claims are intended to be embraced therein.
Claims
1. A pharmaceutical composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles comprising PLA-mPEG, wherein the average size of the nanoparticles is about 100 nm to about 200 nm.
2. 10. The composition of claim 1, wherein the PLA-mPEG comprises about 5% by weight mPEG to about 50% by weight mPEG.
3. 3. The composition of claim 1, wherein the molecular weight of the PLA-mPEG is from about 25,000 Da to about 35,000 Da.
4. The composition of claim 3, wherein the molecular weight of the PLA-mPEG is about 30,000 Da.
5. A pharmaceutical composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles comprising PLGA-mPEG, wherein the average size of the nanoparticles is about 100 nm to about 200 nm.
6. 6. The composition of claim 5, wherein the PLGA has a molar ratio of lactic acid:glycolic acid of about 40:60 to about 60:
40.
7. 7. The composition of claim 6, wherein the PLGA has a molar ratio of lactic acid:glycolic acid of about 50:
50.
8. The composition of any one of claims 5 to 7, wherein the PLGA-mPEG comprises from about 5% by weight mPEG to about 50% by weight mPEG.
9. The composition according to any one of claims 5 to 8, wherein the molecular weight of the PLGA-mPEG is from about 17,000 Da to about 27,000 Da.
10. The composition of claim 9, wherein the molecular weight of the PLGA-mPEG is about 22,000 Da.
11. The composition of any one of claims 1 to 10, comprising about 5% to about 15% by weight of dactinomycin.
12. A composition described in any one of claims 1 to 11, wherein the composition is administered to a subject systemically, intravenously, by injection, or orally.
13. 13. The composition of any one of claims 1 to 12, wherein the composition is administered to a subject once or twice over a period of 1, 2, or 3 weeks, optionally with a 1, 2, 3, or 4 week rest period between administration periods.
14. The composition is administered to a subject, the subject having or at risk of developing mucositis, and optionally i. the subject is being concurrently treated with one or more anti-inflammatory and / or antioxidant agents for symptoms of mucositis; or ii. The subject has been pretreated with one or more anti-inflammatory and / or antioxidant agents for symptoms of mucositis prior to administration of the composition. The composition according to any one of claims 1 to 13.
15. AUC of a subject in which a therapeutically effective dose of dactinomycin is about 0.05 to about 2.0 mg min / L ∞ The composition according to any one of claims 1 to 14,
16. A therapeutically effective amount of dactinomycin has a C of about 1 ng / mL to about 20 ng / mL in a subject. max The composition according to any one of claims 1 to 15,
17. 17. The composition of any one of claims 1 to 16, wherein upon administration to a subject, about 70% to about 80% of the dactinomycin is released from the nanoparticles after 3 days.
18. A composition according to any one of claims 1 to 17 for use in treating bone marrow disorders in a subject.
19. A composition according to any one of claims 1 to 18 for use in treating myelodysplastic syndrome in a subject.
Citation Information
Patent Citations
Polylactic acid microsphere and production thereof
JP1988122620A
Treatment of aml
JP2006503871A
Fullvestrant nanospheres / microspheres, their preparation methods, and use
JP2013503113A
